role,name,affiliation,address,trial_id,processed_name,first_name,gender,gender_probability,gender_sample_count,Rank,NCT Number,Title,Status,Study Results,Conditions,Interventions,First Posted,Locations,URL
Principal Investigator,"Cristiane Takita, MD, MBA",University of Miami,,NCT04360330,cristiane takita,cristiane,female,0.98,1268,1,NCT04360330,SABER Study for Selected Early Stage Breast Cancer,Recruiting,No Results Available,Breast Cancer|Early-stage Breast Cancer,Radiation: Stereotactic Ablative Breast Radiotherapy,"April 24, 2020","University of Miami, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04360330
Principal Investigator,"ANNE TARDIVON, MD",Institut Curie,,NCT04217109,anne tardivon,anne,female,0.97,78727,2,NCT04217109,Transcutaneous Breast Cancer Diagnosis by Canine Odorology,Recruiting,No Results Available,Breast Cancer,Diagnostic Test: Odour sampling,"January 3, 2020","Institut de Cancérologie de l'Ouest, Nantes, France|Centre d'imagerie 114, Paris, France|Groupe Hospitalier Paris Saint- Joseph, Paris, France|Institut Curie, Paris, France|Institut Curie, Saint-Cloud, France|Centre Hospitalier Valenciennes, Valenciennes, France",https://ClinicalTrials.gov/show/NCT04217109
Principal Investigator,"Osama Hussein, MD, PhD",Mansoura University Faculty of Medicine,,NCT04387630,osama hussein,osama,male,0.98,8125,5,NCT04387630,Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.,Recruiting,No Results Available,Breast Cancer,Drug: Metformin|Drug: Placebo oral tablet,"May 14, 2020","Mansoura University Cancer center, Mansoura, Egypt",https://ClinicalTrials.gov/show/NCT04387630
Study Chair,"Michal Mego, Prof","National Cancer Institute, Slovakia",,NCT04265274,michal mego,michal,male,0.99,62499,6,NCT04265274,"Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.",Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Disulfiram|Drug: Vinorelbin|Drug: Cisplatin|Drug: Copper,"February 11, 2020","National Cancer Institute, Bratislava, Slovakia",https://ClinicalTrials.gov/show/NCT04265274
Principal Investigator,"Vanessa A Scontre, MD",Instituto do Cancer do Estado de São Paulo,,NCT04350229,vanessa a scontre,vanessa,female,0.98,123396,10,NCT04350229,Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: Drug omission|Other: Control group,"April 16, 2020","Vanessa Scontre, São Paulo, SP, Brazil",https://ClinicalTrials.gov/show/NCT04350229
Study Chair,"YU Zhiyong, PhD",Shandong Cancer Hospital and Institute,,NCT04302415,yu zhiyong,yu,male,0.54,4500,12,NCT04302415,Metabolomics Explores Biomarkers for Metastatic Breast Cancer,Recruiting,No Results Available,Breast Cancer,"Drug: There is no other intervention, only clinical treatment.","March 10, 2020","Shandong Cancer Hospital and Institute, Jinan, Shandong, China",https://ClinicalTrials.gov/show/NCT04302415
Principal Investigator,"WANG Fukai, MM",Shandong Cancer Hospital and Institute,,NCT04302415,wang fukai,wang,male,0.64,3532,12,NCT04302415,Metabolomics Explores Biomarkers for Metastatic Breast Cancer,Recruiting,No Results Available,Breast Cancer,"Drug: There is no other intervention, only clinical treatment.","March 10, 2020","Shandong Cancer Hospital and Institute, Jinan, Shandong, China",https://ClinicalTrials.gov/show/NCT04302415
Principal Investigator,Yu Jiang,West China Hospital,,NCT04400695,yu jiang,yu,male,0.54,4500,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Yu Wang,Shanxi Province Cancer Hospital,,NCT04400695,yu wang,yu,male,0.54,4500,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Tao Sun,Liaoning Tumor Hospital & Institute,,NCT04400695,tao sun,tao,male,0.86,1883,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Wei Li,First Hospital of Jilin University,,NCT04400695,wei li,wei,male,0.72,5779,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Yuee Teng,First Hospital of China Medical University,,NCT04400695,yuee teng,yuee,female,0.67,12,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Shu Wang,Peking University People's Hospital,,NCT04400695,shu wang,shu,female,0.57,1826,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Xiaojia Wang,Zhejiang Cancer Hospital,,NCT04400695,xiaojia wang,xiaojia,female,0.89,19,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Xichun Hu,Fudan University,,NCT04400695,xichun hu,xichun,male,0.67,3,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Min Yan,Henan Cancer Hospital,,NCT04400695,min yan,min,male,0.57,7493,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Jifeng Feng,Jiangsu Cancer Institute & Hospital,,NCT04400695,jifeng feng,jifeng,male,1.0,5,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Ying Cheng,Jilin Provincial Tumor Hospital,,NCT04400695,ying cheng,ying,female,0.86,3620,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Ying Wang,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,NCT04400695,ying wang,ying,female,0.86,3620,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Shusen Wang,"Cancer prevention and treatment center, sun yat-sen university",,NCT04400695,shusen wang,shusen,male,1.0,4,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Ning Liao,Guangdong Provincial People's Hospital,,NCT04400695,ning liao,ning,female,0.76,1681,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Haibo Wang,Affiliated Hospital of Qingdao University,,NCT04400695,haibo wang,haibo,male,0.98,83,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Yueyin Pan,Anhui Provincial Hospital,,NCT04400695,yueyin pan,yueyin,female,1.0,1,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Yingying Du,The First Affiliated Hospital of Anhui Medical University,,NCT04400695,yingying du,yingying,female,0.98,252,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Changlu Hu,Anhui Cancer Hospital,,NCT04400695,changlu hu,changlu,male,1.0,2,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Zhongsheng Tong,Tianjin Cancer Hospital,,NCT04400695,zhongsheng tong,zhongsheng,male,1.0,6,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Jin Yang,The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine,,NCT04400695,jin yang,jin,male,0.7,7587,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Lihua Song,Shandong Cancer Hospital,,NCT04400695,lihua song,lihua,female,0.82,147,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Xiuwen Wang,Qilu Hospital of Shandong University,,NCT04400695,xiuwen wang,xiuwen,female,0.56,9,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Yunjiang Liu,The Fourth Hospital of Hebei Medical University,,NCT04400695,yunjiang liu,yunjiang,male,1.0,1,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Jing Cheng,"Wuhan Union Hospital, China",,NCT04400695,jing cheng,jing,female,0.75,2653,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Huihua Xiong,"Huazhong University of Science Tongji Hospital, Tongji Medical College",,NCT04400695,huihua xiong,huihua,female,0.85,13,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Xinhong Wu,Hubei Cancer Hospital,,NCT04400695,xinhong wu,xinhong,male,0.6,5,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Peng Shen,First Affiliated Hospital of Zhejiang University School of Medicine,,NCT04400695,peng shen,peng,male,0.84,1286,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Weimin Xie,Cancer Hospital Affiliated to Guangxi Medical University,,NCT04400695,weimin xie,weimin,male,1.0,57,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Xin Zhou,Chongqing University Cancer Hospital,,NCT04400695,xin zhou,xin,female,0.52,1592,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Li Ran,Cancer Hospital of Guizhou Province,,NCT04400695,li ran,li,female,0.63,5785,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Jinnan Gao,Bethune Hospital of Shanxi Province,,NCT04400695,jinnan gao,jinnan,male,0.8,5,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Jingfen Wang,Linyi Cancer Hospital,,NCT04400695,jingfen wang,jingfen,female,1.0,1,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Liangmin Zhang,Yantai Yuhuangding Hospital,,NCT04400695,liangmin zhang,liangmin,female,0.5,4,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Xianhe Xie,First Affiliated Hospital of Fujian Medical University,,NCT04400695,xianhe xie,xianhe,female,1.0,1,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Ru Zeng,The First Affiliated Hospital of Xiamen University,,NCT04400695,ru zeng,ru,male,0.63,605,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Airong Wang,Weihai Municipal Hospital,,NCT04400695,airong wang,airong,male,0.8,5,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Zhengqiu Zhu,Affiliated Hospital of Xuzhou Medical University,,NCT04400695,zhengqiu zhu,zhengqiu,male,1.0,2,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Sanyuan Sun,Xuzhou Central Hospital,,NCT04400695,sanyuan sun,sanyuan,male,1.0,6,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Qingshan Li,Affiliated Hospital of Chengde Medical College,,NCT04400695,qingshan li,qingshan,male,0.89,19,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Aimin Zang,Affiliated Hospital of Hebei University,,NCT04400695,aimin zang,aimin,male,0.84,19,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Liuzhong Yang,The First Affiliated Hospital of Xinxiang Medical College,,NCT04400695,liuzhong yang,liuzhong,male,1.0,1,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Yuping Sun,Jinan Central Hospital,,NCT04400695,yuping sun,yuping,female,0.58,38,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Liang Li,Zibo Central Hospital,,NCT04400695,liang li,liang,male,0.79,1211,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Guohua Yu,Weifang People's Hospital,,NCT04400695,guohua yu,guohua,male,0.56,61,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,Xujuan Wang,Neijiang Second People's Hospital,,NCT04400695,xujuan wang,xujuan,female,1.0,1,67,NCT04400695,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,Not yet recruiting,No Results Available,Breast Cancer,Drug: RC48-ADC|Drug: Paclitaxel Injection|Drug: Docetaxel Injection|Drug: Vinorelbine Tartrate Injection|Drug: Capecitabine Tablets,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04400695
Principal Investigator,"yu Cao, Doctor",the study director of phase I clinical research center,,NCT04420871,yu cao,yu,male,0.54,4500,346,NCT04420871,Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer,Completed,No Results Available,Patient Participation,Drug: 150 mg of Xeloda®|Drug: 150 mg of capecitabine,"June 9, 2020","Phase Ⅰ Clinical Research Center, Qingdao, Shandong, China",https://ClinicalTrials.gov/show/NCT04420871
Principal Investigator,"George Foutzilas, MD",Hellenic Cooperative Oncology Group,,NCT04365790,george foutzilas,george,male,0.98,65488,16,NCT04365790,Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma,Recruiting,No Results Available,Breast Cancer,,"April 28, 2020","George Fountzilas, Athens, Greece",https://ClinicalTrials.gov/show/NCT04365790
Principal Investigator,"George Fountzilas, MD",Hellenic Cooperative Oncology Group,,NCT04403984,george fountzilas,george,male,0.98,65488,173,NCT04403984,Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes,Recruiting,No Results Available,Breast Cancer,,"May 27, 2020","George Fountzilas, Athens, Greece",https://ClinicalTrials.gov/show/NCT04403984
Principal Investigator,Vladimir I Chernov,Tomsk NRMC,,NCT04277338,vladimir i chernov,vladimir,male,0.99,24429,17,NCT04277338,Molecular Imaging of HER2 Expression in Breast Cancer Using Technetium-99m-labelled DARPin HE3-G3 (99mTc-HE3-G3),Enrolling by invitation,No Results Available,Primary Breast Cancer,Diagnostic Test: SPECT,"February 20, 2020","TomskNRMC, Tomsk, Russian Federation",https://ClinicalTrials.gov/show/NCT04277338
Study Director,"Vladimir Semiglazov, Professor",N.N.Petrov Research Institute of Oncology,,NCT04293796,vladimir semiglazov,vladimir,male,0.99,24429,160,NCT04293796,Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB),Recruiting,No Results Available,Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB,Procedure: Vacuum-assisted biopsy,"March 3, 2020","Petr Krivorotko, Saint-Petersburg, Russian Federation",https://ClinicalTrials.gov/show/NCT04293796
Principal Investigator,"Petr Krivorotko, MD,PhD",N.N. Petrov Research Institute of Oncology,,NCT04293796,petr krivorotko,petr,male,0.98,81130,160,NCT04293796,Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB),Recruiting,No Results Available,Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB,Procedure: Vacuum-assisted biopsy,"March 3, 2020","Petr Krivorotko, Saint-Petersburg, Russian Federation",https://ClinicalTrials.gov/show/NCT04293796
Principal Investigator,"Kenneth GA Gilhuijs, PhD",UMC Utrecht,,NCT04223492,kenneth ga gilhuijs,kenneth,male,0.98,20666,18,NCT04223492,Liquid Biopsies and Imaging in Breast Cancer,Recruiting,No Results Available,Breast Cancer,Diagnostic Test: Liquid biopsy|Diagnostic Test: Multi-parametric MRI,"January 10, 2020","Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",https://ClinicalTrials.gov/show/NCT04223492
Study Chair,"Christoph Tausch, MD","Brust-Zentrum, Zürich",,NCT04289935,christoph tausch,christoph,male,1.0,17656,19,NCT04289935,Vacuum Assisted Biopsy Immediately Before Surgery as an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Procedure: Vacuum assisted biopsy (VAB),"February 28, 2020","Kantonsspital Baden, Baden, Switzerland|Universitätsspital Basel, Basel, Switzerland|Bethesda Spital, Basel, Switzerland|IOSI - Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland|Inselspital - Universitätsklinik für Frauenklinik, Bern, Switzerland|Hirslanden Brustzentrum Bern Biel, Bern, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Brustzentrum Thurgau, Frauenfeld, Switzerland|Clinique de Genolier, Genolier, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|Hirslanden Klinik St. Anna, Luzern, Switzerland|Gesundheitszentrum Fricktal, Rheinfelden, Switzerland|Tumor- und Brustzentrum ZeTuP St. Gallen, St. Gallen, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Brustzentrum Ostschweiz, St. Gallen, Switzerland|Brust-Zentrum Seefeld, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT04289935
Principal Investigator,"Songjie Shen, MD","Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",,NCT04429269,songjie shen,songjie,male,0.8,10,22,NCT04429269,A Comparative Study of Mammography and Ultrasound for Breast Cancer Screening and Early Diagnosis,Recruiting,No Results Available,Breast Cancer Diagnosis|Breast Cancer Screening,Diagnostic Test: mammography and ultrasound screening,"June 12, 2020","Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04429269
Principal Investigator,"Ajay Dhakal, MBBS",University of Rochester,,NCT04419181,ajay dhakal,ajay,male,0.99,4648,23,NCT04419181,Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer,Not yet recruiting,No Results Available,HER2-positive Breast Cancer,Drug: Docetaxel|Drug: Carboplatin|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Trastuzumab emtansine,"June 5, 2020",,https://ClinicalTrials.gov/show/NCT04419181
Principal Investigator,DERYA ÇINAR,İzmir Bakırçay University,,NCT04315012,derya çinar,derya,female,0.94,24508,24,NCT04315012,Training With Mobile Application in Breast Cancer,Completed,No Results Available,Breast Cancer,Other: receive mobile app-based education,"March 19, 2020","İzmir Bakırçay University, İzmir, Turkey",https://ClinicalTrials.gov/show/NCT04315012
Principal Investigator,"Catherine UZAN, Md PhD",Pitié Salpêtrière Hospital AP-HP,,NCT04292821,catherine uzan,catherine,female,0.98,50312,25,NCT04292821,BIOPSY SCANNER LLTECH© Technology for Diagnosis of Breast Cancer,Recruiting,No Results Available,Breast Cancer,,"March 3, 2020","Hôpital de la Pitié Salpêtrière, Paris, France",https://ClinicalTrials.gov/show/NCT04292821
Principal Investigator,"Silvia Formenti, M.D.",Weill Cornell Medicine,,NCT04220476,silvia formenti,silvia,female,0.99,120107,26,NCT04220476,CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer,Recruiting,No Results Available,Breast Cancer,Radiation: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Drug: Letrozole 2.5Mg Tab|Drug: Palbociclib 125mg,"January 7, 2020","Weill Cornell Medicine, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04220476
Principal Investigator,"Christiane Matuschek, MD","University Hosptial Duesseldorf, Department of Radiotherapy and Radiooncology",,NCT04261244,christiane matuschek,christiane,female,0.98,17000,27,NCT04261244,NeoRad Breast Cancer Study,Not yet recruiting,No Results Available,Breast Cancer,Radiation: preoperative radiotherapy|Radiation: postoperative radiotherapy,"February 7, 2020","Heinrich Heine University Hospital Duesseldorf, Duesseldorf, Germany",https://ClinicalTrials.gov/show/NCT04261244
Principal Investigator,"Pin ZHANG, MD",Chinese Academy of Medical Sciences,,NCT04437160,pin zhang,pin,male,0.54,1144,31,NCT04437160,Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Epirubicin or Pirarubicin|Drug: Cyclophosphamide,"June 18, 2020","Cancer Hospital & Institute Chinese Academy of Medical Sciences (CAMS), Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04437160
Principal Investigator,Baitha P. Maggadani,"Department of Pharmacy, University of Indonesia",,NCT04312347,baitha p. maggadani,baitha,female,0.67,3,32,NCT04312347,Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels,Recruiting,No Results Available,ER+ Breast Cancer,Drug: Tamoxifen dose adjustment,"March 18, 2020","MRCCC Siloam Hospital Semanggi, Jakarta, DKI Jakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04312347
Principal Investigator,"Zhimin Shao, Professor",Fudan University,,NCT04296175,zhimin shao,zhimin,male,0.81,37,35,NCT04296175,Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE),Recruiting,No Results Available,Triple-negative Breast Cancer,Drug: Epirubicin|Drug: CTX|Drug: Paclitaxel|Drug: ddEpirubicin|Drug: ddCTX|Drug: Paclitaxel(with carbo)|Drug: Carboplatin,"March 5, 2020","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04296175
Principal Investigator,"ZhiMin Shao, MD, PhD",Fudan University,,NCT04403529,zhimin shao,zhimin,male,0.81,37,119,NCT04403529,Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Traditional Chinese Medicine Formulation|Drug: Placebo Formulation,"May 27, 2020","Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04403529
Study Chair,"Herui Yao, PhD","Sun Yat-sen Memorial Hospital,Sun Yat-sen University",,NCT04258163,herui yao,herui,male,1.0,1,37,NCT04258163,Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy,Completed,No Results Available,Metastatic Breast Cancer,Drug: Capecitabine|Drug: Liposomal doxorubicin|Drug: Gemcitabine|Drug: Fulvestrant|Drug: Anastrozole|Drug: Letrozole,"February 6, 2020","First People's Hospital of Foshan, Foshan, Guangdong, China|Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04258163
Study Chair,"Herui Yao, PhD","Sun Yat-sen Memorial Hospital,Sun Yat-sen University",,NCT04263298,herui yao,herui,male,1.0,1,111,NCT04263298,Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Fulvestrant|Drug: Capecitabine Oral Product,"February 10, 2020","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Public Health Institute of Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|Fifth Subsidiary Sun Yat-sen University Hospital, Zhuhai, Guangdong, China",https://ClinicalTrials.gov/show/NCT04263298
Principal Investigator,"Shusen Wang, PhD",Sun Yat-sen University,,NCT04263298,shusen wang,shusen,male,1.0,4,111,NCT04263298,Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Fulvestrant|Drug: Capecitabine Oral Product,"February 10, 2020","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Public Health Institute of Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|Fifth Subsidiary Sun Yat-sen University Hospital, Zhuhai, Guangdong, China",https://ClinicalTrials.gov/show/NCT04263298
Principal Investigator,"Li Ling, PhD",Public Health Institute of Sun Yat-sen University,,NCT04263298,li ling,li,female,0.63,5785,111,NCT04263298,Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Fulvestrant|Drug: Capecitabine Oral Product,"February 10, 2020","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Public Health Institute of Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|Fifth Subsidiary Sun Yat-sen University Hospital, Zhuhai, Guangdong, China",https://ClinicalTrials.gov/show/NCT04263298
Principal Investigator,"Kun Wang, PhD",Guangdong Provincial People's Hospital,,NCT04263298,kun wang,kun,male,0.78,1297,111,NCT04263298,Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Fulvestrant|Drug: Capecitabine Oral Product,"February 10, 2020","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Public Health Institute of Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|Fifth Subsidiary Sun Yat-sen University Hospital, Zhuhai, Guangdong, China",https://ClinicalTrials.gov/show/NCT04263298
Principal Investigator,"Qianjun Chen, PhD",Guangdong Provincial Hospital of Traditional Chinese Medicine,,NCT04263298,qianjun chen,qianjun,female,0.5,2,111,NCT04263298,Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Fulvestrant|Drug: Capecitabine Oral Product,"February 10, 2020","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Public Health Institute of Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|Fifth Subsidiary Sun Yat-sen University Hospital, Zhuhai, Guangdong, China",https://ClinicalTrials.gov/show/NCT04263298
Principal Investigator,"Ruilian Xu, Master",Shenzhen People's Hospital,,NCT04263298,ruilian xu,ruilian,female,1.0,1,111,NCT04263298,Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Fulvestrant|Drug: Capecitabine Oral Product,"February 10, 2020","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Public Health Institute of Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|Fifth Subsidiary Sun Yat-sen University Hospital, Zhuhai, Guangdong, China",https://ClinicalTrials.gov/show/NCT04263298
Principal Investigator,"Peijian Peng, PhD",Fifth Subsidiary Sun Yat-sen University Hospital,,NCT04263298,peijian peng,peijian,male,1.0,5,111,NCT04263298,Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Fulvestrant|Drug: Capecitabine Oral Product,"February 10, 2020","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Public Health Institute of Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|Fifth Subsidiary Sun Yat-sen University Hospital, Zhuhai, Guangdong, China",https://ClinicalTrials.gov/show/NCT04263298
Study Chair,"Zhaohui Zhu, MD,PHD","Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College",,NCT04267900,zhaohui zhu,zhaohui,male,0.77,26,39,NCT04267900,99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: 99mTc-HPArk2,"February 13, 2020","Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04267900
Study Director,"Rabiye Uslu Erdemir, MD",Bülent Ecevit University Department of Nucleer Medicine,,NCT04274946,rabiye uslu erdemir,rabiye,female,0.99,149,41,NCT04274946,Sentinel Lymph Node Biopsy With Hybrid Technique in Breast Cancer,Recruiting,No Results Available,Breast Cancer,Procedure: Sentinel lymph node biopsy,"February 18, 2020","Bülent Ecevit University, Zonguldak, Turkey",https://ClinicalTrials.gov/show/NCT04274946
Principal Investigator,"Hakan Bakkal, MD",Bülent Ecevit University Department of Radiation Oncology,,NCT04274946,hakan bakkal,hakan,male,0.97,121565,41,NCT04274946,Sentinel Lymph Node Biopsy With Hybrid Technique in Breast Cancer,Recruiting,No Results Available,Breast Cancer,Procedure: Sentinel lymph node biopsy,"February 18, 2020","Bülent Ecevit University, Zonguldak, Turkey",https://ClinicalTrials.gov/show/NCT04274946
Principal Investigator,"Hüseyin Engin, MD",Bülent Ecevit University Department of Clinical Oncology,,NCT04274946,hüseyin engin,hüseyin,male,0.92,36,41,NCT04274946,Sentinel Lymph Node Biopsy With Hybrid Technique in Breast Cancer,Recruiting,No Results Available,Breast Cancer,Procedure: Sentinel lymph node biopsy,"February 18, 2020","Bülent Ecevit University, Zonguldak, Turkey",https://ClinicalTrials.gov/show/NCT04274946
Principal Investigator,"Trish Millard, MD",University of Virginia,,NCT04272801,trish millard,trish,female,0.95,1527,42,NCT04272801,Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer,Recruiting,No Results Available,Breast Cancer Female,"Drug: tamoxifen, letrozole, anastrozole, or exemestane|Behavioral: Patient reported outcomes","February 17, 2020","University of Virginia, Charlottesville, Virginia, United States",https://ClinicalTrials.gov/show/NCT04272801
Principal Investigator,"Marleen Kok, MD",NKI-AvL,,NCT04307329,marleen kok,marleen,female,0.99,4046,43,NCT04307329,Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial,Not yet recruiting,No Results Available,Breast Cancer,Biological: Monalizumab|Biological: Trastuzumab,"March 13, 2020","NKI-AVL, Amsterdam, Netherlands",https://ClinicalTrials.gov/show/NCT04307329
Principal Investigator,"Elizabeth Nichols, MD","University of Maryland, Baltimore",,NCT04234386,elizabeth nichols,elizabeth,female,0.99,31288,46,NCT04234386,GammaPod Dose Escalation Radiation for Early Stage Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Radiation: GammaPod Radiation,"January 21, 2020",,https://ClinicalTrials.gov/show/NCT04234386
Principal Investigator,Elizabeth K O'Donnell,Massachusetts General Hospital,,NCT04330339,elizabeth k o'donnell,elizabeth,female,0.99,31288,170,NCT04330339,Prolonged Nightly Fasting in Breast Cancer Survivors,Not yet recruiting,No Results Available,Fasting|Breast Cancer|Survivorship|Breast Cancer Recurrent,Behavioral: Fasting,"April 1, 2020","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04330339
Principal Investigator,"Elizabeth Stone, MD","Cleveland Clinic, Case Comprehensive Cancer Center",,NCT04365569,elizabeth stone,elizabeth,female,0.99,31288,204,NCT04365569,Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program,Not yet recruiting,No Results Available,Breast Cancer,Behavioral: Nutrition and physical activity counseling program,"April 28, 2020","Cleveland Clinic Florida Weston, Case Comprehensive Cancer Center, Weston, Florida, United States",https://ClinicalTrials.gov/show/NCT04365569
Principal Investigator,"Elizabeth J Lyons, PhD, MPH",University of Texas,,NCT04259905,elizabeth j lyons,elizabeth,female,0.99,31288,242,NCT04259905,Pink Warrior 2: Teleconference-based Gaming Support,Recruiting,No Results Available,Breast Cancer|Physical Activity,Behavioral: Active video game teleconference support group|Behavioral: Standard support group + pedometer,"February 7, 2020","The University of Texas Medical Branch, Galveston, Texas, United States",https://ClinicalTrials.gov/show/NCT04259905
Principal Investigator,"Elizabeth A Mittendorf, MD, PhD",Dana-Farber Cancer Institute,,NCT04434040,elizabeth a mittendorf,elizabeth,female,0.99,31288,281,NCT04434040,Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC,Not yet recruiting,No Results Available,Breast Cancer|Triple Negative Breast Cancer|Residual Cancer|Circulating Tumor DNA,Drug: Atezolizumab|Drug: Ipatasertib,"June 16, 2020","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04434040
Principal Investigator,"Francisco Perera, M.D.",Lawson Research Institute,,NCT04339517,francisco perera,francisco,male,0.99,98797,49,NCT04339517,Postoperative Identification of Tumor Cells at the Lumpectomy Site of Patients With Early Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Procedure: Aspiration of seroma fluid,"April 9, 2020",,https://ClinicalTrials.gov/show/NCT04339517
Study Director,"Jian Zhang,MD",Fudan University,,NCT04303988,jian zhang,jian,male,0.9,1562,50,NCT04303988,A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases.,Not yet recruiting,No Results Available,Breast Cancer,Drug: Pyrotinib|Drug: Temozolomide Injection|Drug: SHR-1316|Drug: Bevacizumab|Drug: Cisplatin/Carboplatin,"March 11, 2020",,https://ClinicalTrials.gov/show/NCT04303988
Principal Investigator,"Jian Farhadi, M.D., Prof.","University of Basel, Plastic Surgery Group AG by Prof. Jian Farhadi, Switzerland",,NCT04397419,jian farhadi,jian,male,0.9,1562,307,NCT04397419,Red Bull Energy Drink Intake After Autologous Microsurgical Breast Reconstruction,Recruiting,No Results Available,Breast Cancer,Dietary Supplement: Red Bull Energy Drink|Other: Still water,"May 21, 2020","Klinik Pyramide am See, Zürich, Zurich, Switzerland",https://ClinicalTrials.gov/show/NCT04397419
Principal Investigator,"Fei Xu, MD",Sun Yat-sen University,,NCT04255056,fei xu,fei,male,0.54,1207,53,NCT04255056,Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab,Not yet recruiting,No Results Available,Breast Cancer,Drug: Pyrotinib,"February 5, 2020","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04255056
Principal Investigator,"Fei Xu, MD",Sun Yat-sen University,,NCT04215744,fei xu,fei,male,0.54,1207,207,NCT04215744,Nail Changes Associated With Chemotherapy and Prevention of Nail Pigmentation by Ice Water Immersion,Not yet recruiting,No Results Available,Breast Cancer,Behavioral: Ice water immersion,"January 2, 2020","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04215744
Principal Investigator,"Charis Eng, MD, PhD, FACP","Cleveland Clinic, Case Comprehensive Cancer Center",,NCT04362826,charis eng,charis,male,0.58,848,56,NCT04362826,Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Biological: Novel probiotic|Other: Placebo,"April 27, 2020","Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04362826
Principal Investigator,"Hongping Song, MD",Xijing hospital of The fourth military medical university,,NCT04360616,hongping song,hongping,female,0.67,9,57,NCT04360616,The Diagnosis and Prognosis of Nonpalpable Breast Cancer Detected by the US vs Mammography: a Clinical Noninferiority Trial.,Recruiting,No Results Available,Breast Cancer,Diagnostic Test: imaging,"April 24, 2020","The First Affiliated Hospital of Fourth Military Medical University, Xi'an, Shaanxi, China",https://ClinicalTrials.gov/show/NCT04360616
Principal Investigator,"Hongping Song, MD",Xijing hospital of The fourth military medical university,,NCT04270032,hongping song,hongping,female,0.67,9,71,NCT04270032,"Using Deep Learning Methods to Analyze Automated Breast Ultrasound Images, to Establish a Diagnosis, Therapy Assessment and Prognosis Prediction Model of Breast Cancer.",Recruiting,No Results Available,Breast Cancer,Diagnostic Test: ABUS,"February 17, 2020","The First Affiliated Hospital of Fourth Military Medical University, Xi'an, Shaanxi, China",https://ClinicalTrials.gov/show/NCT04270032
Study Director,"Carmen Chan, PhD",The Chinese University of Hongkong,,NCT04219267,carmen chan,carmen,female,0.98,103801,58,NCT04219267,Effectiveness of Character Strengths-based Intervention Among Breast Cancer Patients,Not yet recruiting,No Results Available,Breast Cancer,Behavioral: character strengths-based intervention|Behavioral: early memories,"January 7, 2020",,https://ClinicalTrials.gov/show/NCT04219267
Study Director,"Ka Ming Chow, PhD",The Chinese University of Hongkong,,NCT04219267,ka ming chow,ka,female,0.61,4428,58,NCT04219267,Effectiveness of Character Strengths-based Intervention Among Breast Cancer Patients,Not yet recruiting,No Results Available,Breast Cancer,Behavioral: character strengths-based intervention|Behavioral: early memories,"January 7, 2020",,https://ClinicalTrials.gov/show/NCT04219267
Study Director,"Carmen Jerónimo, PhD",IPO-Porto,,NCT04298398,carmen jerónimo,carmen,female,0.98,103801,441,NCT04298398,Impact of Group Psychological Interventions on Extracellular Vesicles in People Who Had Cancer,Not yet recruiting,No Results Available,Cancer,Behavioral: Mindfulness Based-Cognitive Therapy (MBCT)|Behavioral: Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|Other: Treatment as usual (no intervention),"March 6, 2020",,https://ClinicalTrials.gov/show/NCT04298398
Study Chair,"Rui Henrique, PhD",IPO-Porto,,NCT04298398,rui henrique,rui,male,0.98,38514,441,NCT04298398,Impact of Group Psychological Interventions on Extracellular Vesicles in People Who Had Cancer,Not yet recruiting,No Results Available,Cancer,Behavioral: Mindfulness Based-Cognitive Therapy (MBCT)|Behavioral: Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|Other: Treatment as usual (no intervention),"March 6, 2020",,https://ClinicalTrials.gov/show/NCT04298398
Study Director,"Eunice Silva, PhD",IPO-Porto,,NCT04298398,eunice silva,eunice,female,0.98,5395,441,NCT04298398,Impact of Group Psychological Interventions on Extracellular Vesicles in People Who Had Cancer,Not yet recruiting,No Results Available,Cancer,Behavioral: Mindfulness Based-Cognitive Therapy (MBCT)|Behavioral: Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|Other: Treatment as usual (no intervention),"March 6, 2020",,https://ClinicalTrials.gov/show/NCT04298398
Study Director,"Goreti Sales, PhD",ISEP-Biomark (Polytecnic Institute of Porto),,NCT04298398,goreti sales,goreti,female,0.98,400,441,NCT04298398,Impact of Group Psychological Interventions on Extracellular Vesicles in People Who Had Cancer,Not yet recruiting,No Results Available,Cancer,Behavioral: Mindfulness Based-Cognitive Therapy (MBCT)|Behavioral: Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|Other: Treatment as usual (no intervention),"March 6, 2020",,https://ClinicalTrials.gov/show/NCT04298398
Principal Investigator,Soo Chin Lee,"National University Hospital, Singapore",,NCT04280536,soo chin lee,soo,female,0.58,2690,59,NCT04280536,Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA),Recruiting,No Results Available,Breast Cancer,Drug: Cohort A|Drug: Cohort B,"February 21, 2020","National University Hospital, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04280536
Principal Investigator,"Jennifer Gass, MD",Women & Infants Hospital,,NCT04397185,jennifer gass,jennifer,female,0.98,90255,62,NCT04397185,Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer Female,Device: Breast Cancer Locator (BCL) guided partial mastectomy|Device: Wire Localized (WL) partial mastectomy,"May 21, 2020",,https://ClinicalTrials.gov/show/NCT04397185
Principal Investigator,Jennifer M Specht,ECOG-ACRIN Cancer Research Group,,NCT04316117,jennifer m specht,jennifer,female,0.98,90255,221,NCT04316117,"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study",Recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,Procedure: Computed Tomography|Other: Fludeoxyglucose F-18|Procedure: Positron Emission Tomography,"March 20, 2020","Carle on Vermilion, Danville, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",https://ClinicalTrials.gov/show/NCT04316117
Principal Investigator,"Robert W Mutter, M.D.",Mayo Clinic Radiation Oncology,,NCT04308720,robert w mutter,robert,male,0.99,177418,65,NCT04308720,Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers in Patients Undergoing Regional Nodal Irradiation for Breast Cancer,Recruiting,No Results Available,Breast Cancer,,"March 16, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04308720
Study Director,"Robert Stagg, PharmD",Tempest Therapeutics,,NCT04344795,robert stagg,robert,male,0.99,177418,403,NCT04344795,Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors,Recruiting,No Results Available,Solid Tumor|Microsatellite-stable Colorectal Cancer (MSS CRC)|Adenocarcinoma of the Lung|Squamous Cell Carcinoma of Head and Neck|Bladder Cancer|Triple Negative Breast Cancer|Gastric Cancer,Drug: TPST-1495|Drug: Pembrolizumab,"April 14, 2020","START Midwest, Grand Rapids, Michigan, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04344795
Study Director,"Robert Sikorski, MD, PhD",Bolt Biotherapeutics,,NCT04278144,robert sikorski,robert,male,0.99,177418,421,NCT04278144,A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors,Recruiting,No Results Available,"Neoplasm, Metastatic|Neoplasm, Breast|Neoplasm, Gastric",Drug: BDC-1001|Drug: Pembrolizumab,"February 20, 2020","Bolt Investigative Site, Grand Rapids, Michigan, United States|Bolt Investigative Site, Pittsburgh, Pennsylvania, United States|Bolt Investigative Site, Houston, Texas, United States|Bolt Investigative Site, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04278144
Principal Investigator,Xichun Hu,Cancer Hospital affiliated to Fudan University,,NCT04382352,xichun hu,xichun,male,0.67,3,85,NCT04382352,B002 in Patients With HER2-positive Breast Cancer,Recruiting,No Results Available,Recurrent Breast Cancer|Metastatic Breast Cancer,Biological: Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002.,"May 11, 2020","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04382352
Principal Investigator,"Min Yan, Professor",Henan Cancer Hospital,,NCT04293276,min yan,min,male,0.57,7493,98,NCT04293276,Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer,Not yet recruiting,No Results Available,Metastatic Breast Cancer,Drug: Pyrotinib|Drug: SHR6390,"March 3, 2020","Henan Cancer Hospital, Zhengzhou, Henan, China",https://ClinicalTrials.gov/show/NCT04293276
Principal Investigator,Min Yan,Henan Cancer Hospital,,NCT04398108,min yan,min,male,0.57,7493,216,NCT04398108,A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC,Not yet recruiting,No Results Available,HER2 Positive Metastatic Breast Cancer,Drug: Margetuximab Margetuximab-IV,"May 21, 2020",,https://ClinicalTrials.gov/show/NCT04398108
Principal Investigator,Cuizhi Geng,The fourth hospital of Hebei Medical University,,NCT04398108,cuizhi geng,cuizhi,female,0.5,2,216,NCT04398108,A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC,Not yet recruiting,No Results Available,HER2 Positive Metastatic Breast Cancer,Drug: Margetuximab Margetuximab-IV,"May 21, 2020",,https://ClinicalTrials.gov/show/NCT04398108
Study Director,"Jin Jin, Ph.D.",ADLAI NORTYE USA INC.,,NCT04432857,jin jin,jin,male,0.7,7587,384,NCT04432857,AN0025 and Pembrolizumab Combination in Advanced Solid Tumors,Not yet recruiting,No Results Available,"Triple-negative Breast Cancer|NSCLC, Squamous or Non-Squamous|Urothelial Carcinoma of the Bladder|Microsatellite Stable (MSS) Colorectal Cancer (CRC)|Cervical Cancer",Drug: AN0025|Drug: Pembrolizumab,"June 16, 2020",,https://ClinicalTrials.gov/show/NCT04432857
Study Chair,"JIHYE HWANG, Professor",Physical & Rehabilitation Medicine Samsung Medical Center,,NCT04316156,jihye hwang,jihye,female,0.98,944,68,NCT04316156,Real-time Interactive Digital Healthcare System in Patients With Breast Cancer; Randomized Controlled Trial,Recruiting,No Results Available,Breast Cancer,Device: Uincare Homeplus|Other: Brochure,"March 20, 2020","Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Department of rehabilitation, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Seocho-gu, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04316156
Principal Investigator,"Filippo de Braud, Professor","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",,NCT04248998,filippo de braud,filippo,male,0.99,27899,69,NCT04248998,Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer,Recruiting,No Results Available,Triple-negative Breast Cancer,Dietary Supplement: Fasting-mimicking diet|Drug: Metformin|Drug: Preoperative chemotherapy,"January 30, 2020","Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy",https://ClinicalTrials.gov/show/NCT04248998
Principal Investigator,"Zahraa Al-Hilli, MD",The Cleveland Clinic,,NCT04354675,zahraa al-hilli,zahraa,female,0.99,334,72,NCT04354675,Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer,Not yet recruiting,No Results Available,Breast Cancer,Genetic: Automated program (ChatBot)|Genetic: Genetics counselor|Other: BCGCKQ Survey|Other: Satisfaction Survey|Genetic: Genetic testing,"April 21, 2020","Cleveland Clinic, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04354675
Principal Investigator,"Christel Fontaine, Dr.",Universitair Ziekenhuis Brussel,,NCT04224922,christel fontaine,christel,female,0.96,9408,75,NCT04224922,Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer,Completed,No Results Available,Breast Cancer,Drug: Paclitaxel|Drug: Carboplatinum|Drug: Epirubicin|Drug: Cyclophosphamide,"January 13, 2020","Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium|Cliniques Sud Luxembourg, Arlon, Belgium|Imelda Ziekenhuis, Bonheiden, Belgium|AZ klina, Brasschaat, Belgium|St Lucas, Brugge, Belgium|Institut Jules Bordet, Brussels, Belgium|Universitaire Ziekenhuis Antwerpen, Edegem, Belgium|AZ Maria Middelares, Gent, Belgium|AZ St Lucas, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHR Citadelle, Liège, Belgium|CHU Sart-Tilman, Liège, Belgium|CMSE, Namur, Belgium|Clinique st Pierre, Ottignies, Belgium|CHWAPI, Tournai, Belgium|CHR Verviers, Verviers, Belgium|CHU Mont-Godinne, Yvoir, Belgium",https://ClinicalTrials.gov/show/NCT04224922
Study Chair,"Michael Pollak, MD",McGill University,,NCT04261218,michael pollak,michael,male,0.99,245870,76,NCT04261218,"Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer",Not yet recruiting,No Results Available,Breast Cancer,Drug: tomivosertib|Drug: paclitaxel,"February 7, 2020","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Vancouver, Vancouver, British Columbia, Canada|Jewish General Hospital, Montreal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04261218
Study Director,"Michael Kurman, MD",Acepodia Biotech Inc.,,NCT04319757,michael kurman,michael,male,0.99,245870,409,NCT04319757,ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors,Recruiting,No Results Available,Locally Advanced Solid Tumor|Metastatic Cancer|Solid Tumor|HER2-positive Gastric Cancer|HER2-positive Metastatic Breast Cancer,Drug: ACE1702|Drug: Cyclophosphamide|Drug: Fludarabine,"March 24, 2020","MD Anderson Cancer Center, Houston, Texas, United States|Peninsula Cancer Institute, Newport News, Virginia, United States",https://ClinicalTrials.gov/show/NCT04319757
Principal Investigator,Antonio LLombart,MedSIR,,NCT04240106,antonio llombart,antonio,male,0.99,328654,79,NCT04240106,"Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-negative,ER-positive) and gBRCA or HDR-positive Metastatic Breast Cancer(LUZERN)",Not yet recruiting,No Results Available,Breast Cancer|Breast Cancer Metastatic,Drug: Niraparib 100 MG|Drug: Aromatase Inhibitors,"January 27, 2020","Centro Oncologico de Galicia, A Coruña, Spain|Hospital Uniersitario Vall d'Hebron, Barcelona, Spain|Hospital Clínic i provincial de Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de octubre, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Clínico Universitario de Santiago de Compostela, Santiago De Compostela, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Complejo Asistencial de Ávila, Ávila, Spain",https://ClinicalTrials.gov/show/NCT04240106
Principal Investigator,Antonio Llombart,MedSIR,,NCT04300790,antonio llombart,antonio,male,0.99,328654,210,NCT04300790,Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients,Not yet recruiting,No Results Available,Breast Cancer,Drug: Alpelisib|Drug: Metformin|Drug: Fulvestrant,"March 9, 2020",,https://ClinicalTrials.gov/show/NCT04300790
Principal Investigator,"Barbara Smith, MD, PhD",Massachusetts General Hospital,,NCT04440982,barbara smith,barbara,female,0.98,94709,84,NCT04440982,Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients Receiving Neoadjuvant Therapy,Not yet recruiting,No Results Available,Breast Cancer|Neoadjuvant Therapy,Combination Product: Study Device Arm,"June 22, 2020","Stanford University Medical Center, Palo Alto, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04440982
Study Director,"Jorge Ferrer, PhD","Lumicell, Inc.",,NCT04440982,jorge ferrer,jorge,male,0.99,118451,84,NCT04440982,Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients Receiving Neoadjuvant Therapy,Not yet recruiting,No Results Available,Breast Cancer|Neoadjuvant Therapy,Combination Product: Study Device Arm,"June 22, 2020","Stanford University Medical Center, Palo Alto, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04440982
Principal Investigator,Miho Asano,SSHSPH NUS,,NCT04269967,miho asano,miho,female,0.92,1055,86,NCT04269967,A Pilot Tele-rehabilitation Trial for Breast Cancer Survivors,Not yet recruiting,No Results Available,Breast Cancer Female,Other: Receiving routine rehabilitation care via tele-rehabilitation system,"February 17, 2020","Miho Asano, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04269967
Principal Investigator,"Francesco Bianco, MD, PhD",ITAB - Institute for Advanced Biomedical Technologies,,NCT04337736,francesco bianco,francesco,male,0.99,196032,89,NCT04337736,Effects of Physical Exercise on Cardio-vascular Efficiency and Quality of Life in Breast Cancer Survivors,Completed,No Results Available,Breast Cancer Female,Other: Physical exercise,"April 8, 2020",,https://ClinicalTrials.gov/show/NCT04337736
Principal Investigator,"Valentina Bucciarelli, MD, PhD",ITAB - Institute for Advanced Biomedical Technologies,,NCT04337736,valentina bucciarelli,valentina,female,0.99,75303,89,NCT04337736,Effects of Physical Exercise on Cardio-vascular Efficiency and Quality of Life in Breast Cancer Survivors,Completed,No Results Available,Breast Cancer Female,Other: Physical exercise,"April 8, 2020",,https://ClinicalTrials.gov/show/NCT04337736
Principal Investigator,"Victoria M Raymond, M.S.",GUARDANT HEALTH,,NCT04436393,victoria m raymond,victoria,female,0.98,35658,90,NCT04436393,Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer,Not yet recruiting,No Results Available,Advanced Breast Cancer,Diagnostic Test: Guardant360 test,"June 18, 2020",,https://ClinicalTrials.gov/show/NCT04436393
Study Chair,"Kunwei Shen, MD,PhD",Ruijin Hospital,,NCT04398914,kunwei shen,kunwei,male,1.0,4,94,NCT04398914,"Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer",Not yet recruiting,No Results Available,Breast Cancer Invasive,Drug: Pyrotinib|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Nab-paclitaxel|Drug: EC chemotherapy|Drug: Physician's choice|Drug: T-DM1|Procedure: Surgery,"May 22, 2020",,https://ClinicalTrials.gov/show/NCT04398914
Principal Investigator,"Marco Colleoni, MD",European Institute of Oncology,,NCT04304352,marco colleoni,marco,male,0.99,357670,97,NCT04304352,"Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients",Recruiting,No Results Available,Advanced Breast Cancer,Drug: Vinorelbine|Drug: Capecitabine|Drug: Cyclophosphamide,"March 11, 2020","European Institute of Oncology, Milan, Italy",https://ClinicalTrials.gov/show/NCT04304352
Study Chair,"Marco Krengli, MD",University of Piemonte Orientale,,NCT04446624,marco krengli,marco,male,0.99,357670,289,NCT04446624,"Oxidative Stress, Anxiety and Depression in Breast Cancer Patients: Impact of Music Therapy",Completed,No Results Available,"Breast Cancer|Depression, Anxiety|Oxidative Stress",Other: Music therapy intervention,"June 25, 2020","Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy",https://ClinicalTrials.gov/show/NCT04446624
Principal Investigator,"Ioannis Boukovinas, Dr /Phd",HeSMO,,NCT04247035,ioannis boukovinas,ioannis,male,0.99,2807,100,NCT04247035,"Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer",Recruiting,No Results Available,Metastatic Breast Cancer,,"January 29, 2020","Hellenic Society of Medical Oncology, Athens, Greece",https://ClinicalTrials.gov/show/NCT04247035
Principal Investigator,"Lubna Chaudhary, MD",Medical College of Wisconsin,,NCT04243616,lubna chaudhary,lubna,female,0.97,625,104,NCT04243616,Study of PD-1 Inhibition With Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant Chemotherapy,Suspended,No Results Available,Invasive Breast Cancer,Drug: Cemiplimab|Drug: Paclitaxel|Drug: Carboplatin (not mandatory)|Drug: Doxorubicin|Drug: Cyclophosphamide,"January 28, 2020","Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04243616
Principal Investigator,"Shail Maingi, MD",St. Peter's Health Partners,,NCT04432727,shail maingi,shail,male,0.94,145,108,NCT04432727,Study Evaluating Flexitouch Plus With Connectivity on Compliance in 30 Patients With Breast Cancer-Related Lymphedema.,Not yet recruiting,No Results Available,Breast Cancer Lymphedema,Device: Flexitouch Plus with Cellular Connectivity (FT-CC),"June 16, 2020",,https://ClinicalTrials.gov/show/NCT04432727
Principal Investigator,"Nicolas Ajkay, MD",University of Louisville,,NCT04432727,nicolas ajkay,nicolas,male,0.99,116713,108,NCT04432727,Study Evaluating Flexitouch Plus With Connectivity on Compliance in 30 Patients With Breast Cancer-Related Lymphedema.,Not yet recruiting,No Results Available,Breast Cancer Lymphedema,Device: Flexitouch Plus with Cellular Connectivity (FT-CC),"June 16, 2020",,https://ClinicalTrials.gov/show/NCT04432727
Principal Investigator,"Olivier TREDAN, MD, PhD",Centre Leon Berard,,NCT04354233,olivier tredan,olivier,male,0.99,76702,109,NCT04354233,A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer,Not yet recruiting,No Results Available,Metastatic Breast Cancer,Device: Physical activity intervention with connected devices,"April 21, 2020","CHU Amiens - Site Nord, Amiens, France|CHU Amiens - Site Sud, Amiens, France|Institut de Cancérologie de l'Ouest (ICO), Angers, France|CHU Avignon, Avignon, France|CHRU Besançon, Besançon, France|CH Fleyriat, Bourg-en-Bresse, France|Centre Léon Bérard (CLB), Lyon, France|Clinique Charcot, Lyon, France|CH Morlaix, Morlaix, France|Institut Godinot, Reims, France|Institut de Cancérologie Lucien Neuwirth (ICLN), Saint-Étienne, France",https://ClinicalTrials.gov/show/NCT04354233
Principal Investigator,"Kim Robien, PhD, RD","Milken Institute School of Public Health, George Washington University",,NCT04268693,kim robien,kim,female,0.56,51609,112,NCT04268693,Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer,Not yet recruiting,No Results Available,Triple Negative Breast Cancer,Other: urine collection,"February 13, 2020","Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, United States",https://ClinicalTrials.gov/show/NCT04268693
Principal Investigator,"Kim Gulis, MD",Region Skåne / Lund University,,NCT04227613,kim gulis,kim,female,0.56,51609,288,NCT04227613,Aspects of Breast-conserving Surgery,Enrolling by invitation,No Results Available,Breast Neoplasm|Cosmetic Outcome|Quality of Life,,"January 13, 2020","Central Hospital of Kristianstad, Kristianstad, Skåne, Sweden",https://ClinicalTrials.gov/show/NCT04227613
Principal Investigator,"Lisa Rydén, Prof",Lund University,,NCT04227613,lisa rydén,lisa,female,0.98,102796,288,NCT04227613,Aspects of Breast-conserving Surgery,Enrolling by invitation,No Results Available,Breast Neoplasm|Cosmetic Outcome|Quality of Life,,"January 13, 2020","Central Hospital of Kristianstad, Kristianstad, Skåne, Sweden",https://ClinicalTrials.gov/show/NCT04227613
Principal Investigator,"Tor Svensjö, PhD",Region Skåne,,NCT04227613,tor svensjö,tor,male,0.95,2123,288,NCT04227613,Aspects of Breast-conserving Surgery,Enrolling by invitation,No Results Available,Breast Neoplasm|Cosmetic Outcome|Quality of Life,,"January 13, 2020","Central Hospital of Kristianstad, Kristianstad, Skåne, Sweden",https://ClinicalTrials.gov/show/NCT04227613
Study Director,"Carmine De Angelis, MD",Federico II University,,NCT04318223,carmine de angelis,carmine,male,0.98,17145,113,NCT04318223,Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy,Recruiting,No Results Available,Metastatic Breast Cancer|Locally Advanced Breast Cancer,Drug: Palbociclib,"March 23, 2020","Nuovo ospedale di Prato - S. Stefano, Prato, Firenze, Italy|Ospedale Civile S. Giovanni di Dio, Frattamaggiore, Napoli, Italy|Centro di Riferimento oncologico, Aviano, Pordenone, Italy|Fondazione del Piemonte per l'Oncologia, Candiolo, Torino, Italy|Ospedale Sacro Cuore di Gesù Fatebenefratelli, Benevento, Italy|A.O. Osp. Riuniti - ASST PAPA GIOVANNI 23, Bergamo, Italy|Ospedale di Brindisi ""Perrino"", Brindisi, Italy|Ospedale Policnico San Martino, Genova, Italy|Ospedale Vito Fazzi, Lecce, Italy|Azienda Ospedaliera Papardo, Messina, Italy|Azienda Ospedaliero - Universitaria di Modena, Modena, Italy|A.O.U. Seconda Universita' degli Studi di Napoli, Napoli, Italy|Azienda Ospedaliera 'A. CARDARELLI', Napoli, Italy|Azienda Ospedaliera dei Colli - P.Monaldi, Napoli, Italy|Istituto Nazionale Tumori IRCCS Pascale, Napoli, Italy|Università degli Studi di Napoli ""Federico II"", Napoli, Italy|A.O.U. Pisana, Pisa, Italy|Istituto Nazionale Tumori Regina Elena (IRE, Roma, Italy|Ospedale Sandro Pertini, Roma, Italy",https://ClinicalTrials.gov/show/NCT04318223
Principal Investigator,"Alexander Philipovskiy, MD, PhD","Texas Tech University Health Sciences Center, El Paso",,NCT04362462,alexander philipovskiy,alexander,male,0.99,66065,115,NCT04362462,Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer,Recruiting,No Results Available,Triple-negative Breast Cancer,,"April 27, 2020","Texas Tech University Health Sciences Center- El Paso, El Paso, Texas, United States",https://ClinicalTrials.gov/show/NCT04362462
Principal Investigator,Jinsong Lu,RenJi Hospital,,NCT04254263,jinsong lu,jinsong,male,0.91,22,116,NCT04254263,Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer,Not yet recruiting,No Results Available,Locally Advanced Breast Cancer,Drug: pyrotinib,"February 5, 2020","Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04254263
Principal Investigator,"Caroline ROUSSEAU, MD, PhD",Institut de Cancerologie de l'Ouest,,NCT04320030,caroline rousseau,caroline,female,0.98,64753,120,NCT04320030,[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers,Not yet recruiting,No Results Available,Triple Negative Breast Cancer,Drug: [18F]-DPA-714 PET/CT scan,"March 24, 2020","Institut de Cacerologie de l'ouest - site Paul Papin, Angers, France|APHP - Hôpital Tenon, Paris, France|Institut de cancerologie de l'Ouest, Saint Herblain, France|CHU Bretonneau, Tours, France",https://ClinicalTrials.gov/show/NCT04320030
Principal Investigator,Caroline ROUSSEAU,caroline.rousseau@ico.unicancer.fr,,NCT04226222,caroline rousseau,caroline,female,0.98,64753,152,NCT04226222,Bringing of PET-TDM FDG in the Determination of the Characteristics of Primary Mammary Tumors TrIple Negatives,Recruiting,No Results Available,Breast Cancer,Diagnostic Test: TEP-TDM FDG,"January 13, 2020","Institut de Cancerologie de L'Ouest, Saint-Herblain, France",https://ClinicalTrials.gov/show/NCT04226222
Study Director,Caroline Bordin-Goffin,IFMK Saint Martin d'Hères,,NCT04444882,caroline bordin-goffin,caroline,female,0.98,64753,167,NCT04444882,"Complications After Lumpectomy, Sentinel Node and Radiotherapy in Breast Cancer Patients and Physiotherapy Care",Not yet recruiting,No Results Available,Breast Neoplasm,,"June 24, 2020",,https://ClinicalTrials.gov/show/NCT04444882
Principal Investigator,"Janis O'Malley, MD",University of Alabama at Birmingham,,NCT04332588,janis o'malley,janis,male,0.69,3530,122,NCT04332588,Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI,Not yet recruiting,No Results Available,HER2-positive Breast Cancer,Drug: [18F]FMISO PET/MRI imaging,"April 2, 2020","The University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04332588
Principal Investigator,"Leonel Hernandez Aya, M.D.",Washington University School of Medicine,,NCT04331067,leonel hernandez aya,leonel,male,0.98,3876,124,NCT04331067,Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer,Not yet recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Paclitaxel|Drug: Carboplatin|Biological: Nivolumab|Biological: Cabiralizumab|Procedure: Tumor biopsy|Procedure: Bone marrow|Procedure: Blood draw,"April 2, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04331067
Principal Investigator,Zeynep Olcer,Istanbul University,,NCT04297657,zeynep olcer,zeynep,female,0.97,31807,125,NCT04297657,Using BETTER Model Sexual Problems in Breast Cancer,Completed,No Results Available,Sexuality|Breast Cancer,Other: Counselling,"March 5, 2020",,https://ClinicalTrials.gov/show/NCT04297657
Principal Investigator,"Neil Iyengar, MD",Memorial Sloan Kettering Cancer Center,,NCT04298086,neil iyengar,neil,male,0.99,15028,126,NCT04298086,A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer,Recruiting,No Results Available,Breast Cancer|Primary Hormone Receptor Positive Breast Cancer,Other: Exercise Treatment|Other: Plant-Based Diet|Other: Physical activity|Other: Nutrition counseling,"March 6, 2020","Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States",https://ClinicalTrials.gov/show/NCT04298086
Principal Investigator,"Vida Henderson, PhD",University of Illinois at Chicago,,NCT04378751,vida henderson,vida,female,0.86,3143,127,NCT04378751,Promoting Genetic Counseling Among African American Women With a Family History of Breast Cancer,Not yet recruiting,No Results Available,High Risk for Breast Cancer,Behavioral: Decision aid video|Other: Genetic counseling informational brochure,"May 7, 2020","UIC Cancer Center, Chicago, Illinois, United States|University of Illinois at Chicago Hospital and Ambulatory Clinics, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04378751
Principal Investigator,"Oana Danciu, MD",University of Illinois at Chicago,,NCT04427293,oana danciu,oana,female,0.97,10756,129,NCT04427293,Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC),Not yet recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Lenvatinib|Drug: Pembrolizumab,"June 11, 2020",,https://ClinicalTrials.gov/show/NCT04427293
Principal Investigator,"Ketki D Raina, PhD, OTR/L",University of Toledo,,NCT04232319,ketki d raina,ketki,female,0.95,19,130,NCT04232319,Feasibility and Effectiveness of a Sleep Hygiene Education Program for Sleep Issues in Breast Cancer Survivors,Recruiting,No Results Available,Breast Cancer|Sleep Hygiene,Behavioral: Sleep Hygiene Training,"January 18, 2020","University of Toledo, Toledo, Ohio, United States",https://ClinicalTrials.gov/show/NCT04232319
Principal Investigator,"Alice Y Ho, MD, MBA",Massachusetts General Hospital,,NCT04443348,alice y ho,alice,female,0.98,68971,132,NCT04443348,Pre-op Pembro + Radiation Therapy in Breast Cancer,Not yet recruiting,No Results Available,"Triple Negative Breast Cancer|Hormone Receptor Positive (HR+), HER2-negative Breast Cancer|Biopsy-proven, Positive Lymph Node(s)",Radiation: Radiation Therapy Boost|Drug: Pembrolizumab|Drug: Paclitaxel|Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Doxorubicin,"June 23, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04443348
Principal Investigator,"Anna Sorace, PhD",University of Alabama at Birmingham,,NCT04273555,anna sorace,anna,female,0.98,383713,134,NCT04273555,Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging,Not yet recruiting,No Results Available,HER2-positive Breast Cancer,Drug: [18F]-FDG,"February 18, 2020","The University of Alabama at Birmingham, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04273555
Principal Investigator,"Anna Weiss, MD",Dana-Farber Cancer Institute,,NCT04245176,anna weiss,anna,female,0.98,383713,171,NCT04245176,Genetic Testing for All Breast Cancer Patients (GET FACTS),Recruiting,No Results Available,Breast Cancer|Invasive Breast Cancer|in Situ Breast Cancer|Genetic Testing,Behavioral: Standard Genetic Counseling|Behavioral: Quantitative Genetic Counseling,"January 28, 2020","Dana Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04245176
Study Director,Anna Resch,Pierre Fabre Pharma GmbH,,NCT04388384,anna resch,anna,female,0.98,383713,258,NCT04388384,Real-life Pan-HER-blockade With Neratinib,Recruiting,No Results Available,Breast Neoplasm,Drug: Neratinib,"May 14, 2020","Medical Practice, Landshut, Bavaria, Germany|Medical Practice, Goslar, Lower Saxony, Germany",https://ClinicalTrials.gov/show/NCT04388384
Principal Investigator,"Sarah Sammons, MD",Duke University,,NCT04352777,sarah sammons,sarah,female,0.98,174584,137,NCT04352777,Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer,Not yet recruiting,No Results Available,Metastatic Breast Cancer|Locally Advanced Breast Cancer|Hormone Receptor Positive Tumor,Drug: Abemaciclib|Drug: Fulvestrant|Drug: Aromatase Inhibitors,"April 20, 2020","Duke University Medical Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04352777
Principal Investigator,"Sarah Sammons, MD",Duke University,,NCT04434560,sarah sammons,sarah,female,0.98,174584,448,NCT04434560,Neoadjuvant Immunotherapy in Brain Metastases,Not yet recruiting,No Results Available,"Brain Metastases, Adult",Drug: Nivolumab|Drug: Ipilimumab,"June 17, 2020","Duke University Medical Center, Durham, North Carolina, United States",https://ClinicalTrials.gov/show/NCT04434560
Principal Investigator,"Xuexin He, MD",The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU),,NCT04337658,xuexin he,xuexin,male,0.6,5,138,NCT04337658,"Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer",Not yet recruiting,No Results Available,HER2-positive Breast Cancer,Drug: Pertuzumab|Drug: Trastuzumab|Drug: Fulvestrant|Drug: Capecitabine,"April 8, 2020","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China",https://ClinicalTrials.gov/show/NCT04337658
Principal Investigator,"Jiajia Huang, MD",Sun Yat-sen University,,NCT04337658,jiajia huang,jiajia,female,0.78,185,138,NCT04337658,"Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer",Not yet recruiting,No Results Available,HER2-positive Breast Cancer,Drug: Pertuzumab|Drug: Trastuzumab|Drug: Fulvestrant|Drug: Capecitabine,"April 8, 2020","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China",https://ClinicalTrials.gov/show/NCT04337658
Study Director,"Gustav Dobos, Prof. MD","Department of Internal and Integrative Medicine, Evang. Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen",,NCT04319510,gustav dobos,gustav,male,0.98,2901,140,NCT04319510,Supportive Effects of Craniosacral Therapy for Female Patients With Breast Cancer and Their Partners,Not yet recruiting,No Results Available,Breast Cancer|Complementary Therapies,Procedure: Craniosacral therapy|Procedure: Craniosacral self-help group training|Procedure: Treatment as usal / wait list,"March 24, 2020","Department of Internal and Integrative Medicine, Evang. Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Essen, NRW, Germany",https://ClinicalTrials.gov/show/NCT04319510
Study Chair,"Nurjati Chairani Siregar, MD","Department of Pathology, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia",,NCT04418089,nurjati chairani siregar,nurjati,male,1.0,1,143,NCT04418089,Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer,Completed,No Results Available,Breast Cancer|Chemotherapy Effect,Drug: Simvastatin 40mg|Drug: Placebo oral capsule,"June 5, 2020","Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04418089
Study Chair,Baju Adji,"Department of Surgery, Koja General Hospital, Jakarta, Indonesia",,NCT04418089,baju adji,baju,female,0.56,34,143,NCT04418089,Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer,Completed,No Results Available,Breast Cancer|Chemotherapy Effect,Drug: Simvastatin 40mg|Drug: Placebo oral capsule,"June 5, 2020","Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04418089
Study Chair,"Filipus Dasawala, MD","Department of Surgery, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia",,NCT04418089,filipus dasawala,filipus,male,1.0,33,143,NCT04418089,Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer,Completed,No Results Available,Breast Cancer|Chemotherapy Effect,Drug: Simvastatin 40mg|Drug: Placebo oral capsule,"June 5, 2020","Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04418089
Study Chair,"Hanifah Hasan, MD","Internship Program as Research Assistant, Department of Surgery, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia",,NCT04418089,hanifah hasan,hanifah,female,0.97,99,143,NCT04418089,Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer,Completed,No Results Available,Breast Cancer|Chemotherapy Effect,Drug: Simvastatin 40mg|Drug: Placebo oral capsule,"June 5, 2020","Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04418089
Study Chair,"Muhammad Rizki Kamil, MD","Internship Program as Research Assistant, Department of Surgery, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia",,NCT04418089,muhammad rizki kamil,muhammad,male,0.99,32597,143,NCT04418089,Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer,Completed,No Results Available,Breast Cancer|Chemotherapy Effect,Drug: Simvastatin 40mg|Drug: Placebo oral capsule,"June 5, 2020","Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04418089
Principal Investigator,"Ruben Martin Payo, PhD",University of Oviedo,,NCT04396665,ruben martin payo,ruben,male,0.99,60998,149,NCT04396665,Breast Cancer: Feasibility of an Educational Intervention,Enrolling by invitation,No Results Available,Women's Health: Neoplasm of Breast,Behavioral: Precam,"May 20, 2020","University of Oviedo, Oviedo, Asturias, Spain",https://ClinicalTrials.gov/show/NCT04396665
Principal Investigator,Mehdi Pasalar,Shiraz University of Medical Sciences,,NCT04426435,mehdi pasalar,mehdi,male,0.98,48418,150,NCT04426435,Effects a Honey Based Syrup on Blood Parameters in Patients With Breast Cancer,Recruiting,No Results Available,Breast Cancer,Drug: honey based (HB) syrup,"June 11, 2020","Shohaday-e- Tajrish Hospital, Tehran, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04426435
Study Chair,"Monika Klinkhammer-Schalke, MD, Prof.",Tumor Center Regensburg,,NCT04334096,monika klinkhammer-schalke,monika,female,0.98,148481,151,NCT04334096,Long-term Improvement of Quality of Life in Breast Cancer Patients With Quality of Life Diagnosis and Therapy,"Active, not recruiting",No Results Available,Quality of Life|Breast Cancer|Breast Neoplasms,Behavioral: quality of life pathway,"April 6, 2020","Tumor Center Regensburg, Institute of Quality Management and Health Services Research of the University of Regensburg, Regensburg, Bavaria, Germany",https://ClinicalTrials.gov/show/NCT04334096
Principal Investigator,"Patricia Lindberg-Scharf, PhD",Tumor Center Regensburg,,NCT04334096,patricia lindberg-scharf,patricia,female,0.98,132232,151,NCT04334096,Long-term Improvement of Quality of Life in Breast Cancer Patients With Quality of Life Diagnosis and Therapy,"Active, not recruiting",No Results Available,Quality of Life|Breast Cancer|Breast Neoplasms,Behavioral: quality of life pathway,"April 6, 2020","Tumor Center Regensburg, Institute of Quality Management and Health Services Research of the University of Regensburg, Regensburg, Bavaria, Germany",https://ClinicalTrials.gov/show/NCT04334096
Principal Investigator,"Brunhilde Steinger, MD",Tumor Center Regensburg,,NCT04334096,brunhilde steinger,brunhilde,female,0.95,220,151,NCT04334096,Long-term Improvement of Quality of Life in Breast Cancer Patients With Quality of Life Diagnosis and Therapy,"Active, not recruiting",No Results Available,Quality of Life|Breast Cancer|Breast Neoplasms,Behavioral: quality of life pathway,"April 6, 2020","Tumor Center Regensburg, Institute of Quality Management and Health Services Research of the University of Regensburg, Regensburg, Bavaria, Germany",https://ClinicalTrials.gov/show/NCT04334096
Principal Investigator,Patricia A Ganz,UCLA / Jonsson Comprehensive Cancer Center,,NCT04290897,patricia a ganz,patricia,female,0.98,132232,252,NCT04290897,Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors,Not yet recruiting,No Results Available,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8,Drug: Anhydrous Enol-oxaloacetate|Other: Questionnaire Administration,"March 2, 2020","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04290897
Principal Investigator,"Amparo Garcia-Tejedor, MDPhD",Hospital Universitari Bellvitge,,NCT04389216,amparo garcia-tejedor,amparo,female,0.98,9043,153,NCT04389216,Radiofrequency Ablation (RFA) in Breast Tumors,Recruiting,No Results Available,Breast Cancer Female,Device: Cool-tip electrode for Radiofrequency Ablation,"May 15, 2020","Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04389216
Study Director,khaled fares,Assiut University,,NCT04275661,khaled fares,khaled,male,0.98,37302,155,NCT04275661,Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery,Recruiting,No Results Available,Analgesia|Breast Cancer,Procedure: Ultrasound (US) bi-level erector spinae block|Drug: levobupivacaine|Drug: Ketamine|Drug: Magnesium Sulfate,"February 19, 2020","south Egypt Cancer Institute Assiut University, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04275661
Study Director,hamdy abbas,Assiut University,,NCT04275661,hamdy abbas,hamdy,male,0.96,1008,155,NCT04275661,Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery,Recruiting,No Results Available,Analgesia|Breast Cancer,Procedure: Ultrasound (US) bi-level erector spinae block|Drug: levobupivacaine|Drug: Ketamine|Drug: Magnesium Sulfate,"February 19, 2020","south Egypt Cancer Institute Assiut University, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04275661
Study Director,fatma adel,Assiut University,,NCT04275661,fatma adel,fatma,female,0.97,34628,155,NCT04275661,Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery,Recruiting,No Results Available,Analgesia|Breast Cancer,Procedure: Ultrasound (US) bi-level erector spinae block|Drug: levobupivacaine|Drug: Ketamine|Drug: Magnesium Sulfate,"February 19, 2020","south Egypt Cancer Institute Assiut University, Assiut, Egypt",https://ClinicalTrials.gov/show/NCT04275661
Principal Investigator,"Gregory J Czarnota, PhD, MD",Sunnybrook Health Sciences Centre,,NCT04428528,gregory j czarnota,gregory,male,0.99,25701,156,NCT04428528,Pilot Study to Evaluate Photoacoustic Imaging for Characterizing Breast Masses and Breast Tumor Response to Neoadjuvant Chemotherapy Pilot Study to Evaluate Photoacoustic Imaging for Characterizing Breast Masses and Breast Tumor Response to Neoadjuvant Chemotherapy,Recruiting,No Results Available,Breast Cancer,,"June 11, 2020","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04428528
Principal Investigator,"Gregory S Karczmar, PhD",University of Chicago,,NCT04350957,gregory s karczmar,gregory,male,0.99,25701,315,NCT04350957,Low-dose Imaging Technique (LITE),Not yet recruiting,No Results Available,Breast Cancer,Diagnostic Test: Low-dose Imaging,"April 17, 2020",,https://ClinicalTrials.gov/show/NCT04350957
Principal Investigator,"Deepa Sheth, MD",University of Chicago,,NCT04350957,deepa sheth,deepa,female,0.93,592,315,NCT04350957,Low-dose Imaging Technique (LITE),Not yet recruiting,No Results Available,Breast Cancer,Diagnostic Test: Low-dose Imaging,"April 17, 2020",,https://ClinicalTrials.gov/show/NCT04350957
Principal Investigator,"Betul Kozanhan, M.D.",SBÜ Konya EAH,,NCT04336917,betul kozanhan,betul,female,0.95,1232,159,NCT04336917,Ultrasound Guided Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Surgeries,Recruiting,No Results Available,Breast Cancer Surgery|Postoperative Analgesia,Drug: Rhomboid Intercostal and Subserratus Plane Block with local anesthetic,"April 7, 2020","Konya Education and Training Hospital, Konya, Turkey",https://ClinicalTrials.gov/show/NCT04336917
Principal Investigator,"Chirag C Shah, MD",The Cleveland Clinic,,NCT04245150,chirag c shah,chirag,male,1.0,809,162,NCT04245150,Assessing the Impact of the Microbiome on Breast Cancer Radiotherapy Toxicity,Recruiting,No Results Available,DCIS|Invasive Breast Cancer,Other: Stool sample|Other: Skin Swab Sample,"January 28, 2020","Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04245150
Principal Investigator,"Chirag Shah, MD","Cleveland Clinic, Case Comprehensive Cancer Center",,NCT04348123,chirag shah,chirag,male,1.0,809,316,NCT04348123,"Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography",Not yet recruiting,No Results Available,Breast Cancer,Other: Survey|Behavioral: Education Session,"April 15, 2020","Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04348123
Principal Investigator,"Xingfei Yu, M.D.",Zhejiang Cancer Hospital,,NCT04249440,xingfei yu,xingfei,female,0.5,2,164,NCT04249440,Systemic Treatment Preoperatively vs Postoperatively in HER2 Positive Early Breast Cancer,Completed,No Results Available,Breast Cancer|HER2|Preoperative Systemic Treatment,Procedure: Preoperative systemic treatment,"January 31, 2020",,https://ClinicalTrials.gov/show/NCT04249440
Principal Investigator,Karen M Basen-Engquist,M.D. Anderson Cancer Center,,NCT04267796,karen m basen-engquist,karen,female,0.95,48557,166,NCT04267796,Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women,Recruiting,No Results Available,Breast Carcinoma,Other: Aerobic Exercise|Other: Dietary Intervention|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Other: Resistance Training,"February 13, 2020","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04267796
Principal Investigator,"Karen Daily, DO",University of Florida,,NCT04333706,karen daily,karen,female,0.95,48557,276,NCT04333706,"A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)",Not yet recruiting,No Results Available,Breast|Metastatic|Triple Negative|Cancer|Disseminated Tumor Cell,Drug: Capecitabine|Combination Product: Sarilumab 150mg or 200 mg plus Capecitabine|Combination Product: Sarilumab 150mg plus Capecitabine,"April 3, 2020","UF Health, Gainesville, Florida, United States",https://ClinicalTrials.gov/show/NCT04333706
Study Director,"David Tran, MD, PhD",University of Florida,,NCT04333706,david tran,david,male,0.99,501011,276,NCT04333706,"A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)",Not yet recruiting,No Results Available,Breast|Metastatic|Triple Negative|Cancer|Disseminated Tumor Cell,Drug: Capecitabine|Combination Product: Sarilumab 150mg or 200 mg plus Capecitabine|Combination Product: Sarilumab 150mg plus Capecitabine,"April 3, 2020","UF Health, Gainesville, Florida, United States",https://ClinicalTrials.gov/show/NCT04333706
Principal Investigator,"Karen Sepucha, PhD",Massachusetts General Hospital,,NCT04317690,karen sepucha,karen,female,0.95,48557,417,NCT04317690,Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey,Enrolling by invitation,No Results Available,High Cholesterol|High Blood Pressure|Colorectal Cancer|Breast Cancer|Prostate Cancer,,"March 23, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04317690
Principal Investigator,"Bonnie Ky, MD, MSCE",University of Pennsylvania,,NCT04361240,bonnie ky,bonnie,female,0.9,3712,168,NCT04361240,Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Ancillary Study,Not yet recruiting,No Results Available,Breast Cancer|Cardiotoxicity,Radiation: Proton vs Photon Radiation,"April 24, 2020","Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04361240
Principal Investigator,"Samir E Shehata, Professor",Assiut University,,NCT04316247,samir e shehata,samir,male,0.98,56483,174,NCT04316247,"Demographic , Clinicopathological Characteristics and Survival of Breast Cancer",Not yet recruiting,No Results Available,Breast Carcinoma,,"March 20, 2020",,https://ClinicalTrials.gov/show/NCT04316247
Principal Investigator,"Smitha Menon, MD",Medical College of Wisconsin,,NCT04316169,smitha menon,smitha,female,0.98,131,176,NCT04316169,Hydroxychloroquine (HCQ) in Combination With Abemaciclib and Endocrine Therapy in HR+/Her 2- Advanced Breast Cancer After a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors,Not yet recruiting,No Results Available,Solid Tumor|Advanced Breast Cancer,Drug: Abemaciclib|Drug: Hydroxychloroquine|Drug: Faslodex|Drug: Anastrazole|Drug: Letrozole,"March 20, 2020",,https://ClinicalTrials.gov/show/NCT04316169
Principal Investigator,"Marie-Jeanne T.F.D. Vrancken Peeters, MD, PhD",Antoni van Leeuwenhoek,,NCT04225858,marie-jeanne t.f.d. vrancken peeters,marie-jeanne,female,0.98,925,178,NCT04225858,Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy,Not yet recruiting,No Results Available,Breast Cancer|Triple Negative Breast Cancer|HER2-positive Breast Cancer|Sentinel Lymph Node,Procedure: Omission of sentinel lymph node biopsy,"January 13, 2020",,https://ClinicalTrials.gov/show/NCT04225858
Principal Investigator,"Juliette Haudebourg, MD",Centre Antoine Lacassagne,,NCT04246606,juliette haudebourg,juliette,female,0.97,13500,181,NCT04246606,Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer,Recruiting,No Results Available,Breast Neoplasm Female,Diagnostic Test: IHC4 score,"January 29, 2020","Centre Antoine Lacassagne, Nice, France",https://ClinicalTrials.gov/show/NCT04246606
Principal Investigator,Senthilkumar Damodaran,M.D. Anderson Cancer Center,,NCT04256941,senthilkumar damodaran,senthilkumar,male,0.99,149,182,NCT04256941,"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study",Recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,Drug: Abemaciclib|Drug: Anastrozole|Drug: Fulvestrant|Drug: Letrozole|Drug: Palbociclib|Drug: Ribociclib,"February 5, 2020","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04256941
Principal Investigator,Senthilkumar Damodaran,M.D. Anderson Cancer Center,,NCT04216472,senthilkumar damodaran,senthilkumar,male,0.99,149,274,NCT04216472,Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations,Recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Refractory Breast Carcinoma|Triple-Negative Breast Carcinoma,Drug: Alpelisib|Drug: Nab-paclitaxel,"January 2, 2020","M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04216472
Principal Investigator,"Dominique COHEN, MD",Institut Paoli-Calmettes,,NCT04235946,dominique cohen,dominique,male,0.57,51398,183,NCT04235946,Feasibility Study of an Adapted and Supported Water Polo Program to Reduce Fatigue Related to Cancer and Improve Psychological and Social Recovery in Patients With Breast Cancer Remission,Not yet recruiting,No Results Available,Cancer Related Fatigue|Breast Cancer,Other: accompanied and adapted water polo program,"January 22, 2020","Cercle des nageurs de Marseille, Marseille, France",https://ClinicalTrials.gov/show/NCT04235946
Principal Investigator,PHILIPPE GUILBERT,Institut Jean-Godinot,,NCT04408560,philippe guilbert,philippe,male,0.99,82618,184,NCT04408560,Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer,Recruiting,No Results Available,Breast Cancer Female|Joint Pain,Drug: Rhus toxicodendron 9 CH + Ruta graveolens 5 CH (Homeopathic Granules)|Other: paracetamol (drug analgesic class1),"May 29, 2020","Philippe GUILBERT, Reims, France",https://ClinicalTrials.gov/show/NCT04408560
Principal Investigator,"Abdulmajeed Dayyat, MD",King Hussein Cancer Center,,NCT04424732,abdulmajeed dayyat,abdulmajeed,male,0.99,278,186,NCT04424732,SBRT for Breast Cancer Oligometastases,Recruiting,No Results Available,Breast Neoplasm Malignant Female,Radiation: Stereotactic Body Radiotherapy,"June 11, 2020","King Hussein Cancer Center, Amman, Jordan",https://ClinicalTrials.gov/show/NCT04424732
Principal Investigator,"Birgitte V Offersen, phd",Danish Breast cancer Cooperation Group (DBCG),,NCT04291378,birgitte v offersen,birgitte,female,0.98,915,189,NCT04291378,The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer,Not yet recruiting,No Results Available,Early Breast Cancer|Radiation Associated Cardiac Failure,Radiation: Proton versus photon radiation therapy,"March 2, 2020","Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|The Danish Breast Cancer Cooperative Group, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark|Naestved Hospital, Naestved, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark",https://ClinicalTrials.gov/show/NCT04291378
Principal Investigator,Ahmed Salman,"National Cancer Institute, Cairo Uneversity",,NCT04238377,ahmed salman,ahmed,male,0.98,139051,192,NCT04238377,Post Mastectomy Pain Syndrome After Preoperative Stellate Ganglion Block for Breast Cancer Surgeries,Recruiting,No Results Available,Breast Cancer|Breast Pain,Procedure: Stellate Ganglion Block|Drug: Multimodal Analgesia,"January 23, 2020","National Cancer Institute Cairo University, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04238377
Principal Investigator,"Shifang Yuan, Ph.D",Xijing Hospital,,NCT04239105,shifang yuan,shifang,female,0.75,4,194,NCT04239105,Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device,Not yet recruiting,No Results Available,Breast Neoplasms|Circulating Tumor Cells,Device: Microfluidic and Raman spectrum,"January 23, 2020",,https://ClinicalTrials.gov/show/NCT04239105
Study Chair,Zheng zhuanfang,Second Clinical College of Guangzhou University of Traditional Chinese Medicine,,NCT04442035,zheng zhuanfang,zheng,male,0.75,828,195,NCT04442035,5-element Music Therapy on Patients With Breast Cancer,Completed,No Results Available,"Breast Cancer Female|Quality of Life|Depression, Anxiety",Behavioral: 5-element music therapy,"June 22, 2020","Guangdong Provincial Chinese medicine hospital, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04442035
Study Director,"Isabelle Demeestere, MD, PhD",CUB-Hôpital Erasme,,NCT04289805,isabelle demeestere,isabelle,female,0.99,89728,196,NCT04289805,Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE),Recruiting,No Results Available,Breast Neoplasm Malignant Female,Drug: Letrozole|Other: standard-stimulated cohort,"February 28, 2020","CUB-Hôpital Erasme, Brussel, Belgium|CHC-Saint Vincent, Liège, Belgium|Centre Oscar Lambret, Lille, France|CHRU Lille, Lille, France",https://ClinicalTrials.gov/show/NCT04289805
Study Chair,"Matteo Lambertini, MD, PhD",ULB,,NCT04289805,matteo lambertini,matteo,male,0.99,69199,196,NCT04289805,Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE),Recruiting,No Results Available,Breast Neoplasm Malignant Female,Drug: Letrozole|Other: standard-stimulated cohort,"February 28, 2020","CUB-Hôpital Erasme, Brussel, Belgium|CHC-Saint Vincent, Liège, Belgium|Centre Oscar Lambret, Lille, France|CHRU Lille, Lille, France",https://ClinicalTrials.gov/show/NCT04289805
Study Chair,"Christine Decanter, MD",CHRU Lille,,NCT04289805,christine decanter,christine,female,0.99,91004,196,NCT04289805,Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE),Recruiting,No Results Available,Breast Neoplasm Malignant Female,Drug: Letrozole|Other: standard-stimulated cohort,"February 28, 2020","CUB-Hôpital Erasme, Brussel, Belgium|CHC-Saint Vincent, Liège, Belgium|Centre Oscar Lambret, Lille, France|CHRU Lille, Lille, France",https://ClinicalTrials.gov/show/NCT04289805
Study Chair,"Thorsten Kühn, Prof.",EUROPEAN BREAST CANCER RESEARCH ASSOCIATION OF SURGICAL TRIALISTS,,NCT04373655,thorsten kühn,thorsten,male,1.0,9772,199,NCT04373655,AXillary Surgery After NeoAdjuvant Treatment,Recruiting,No Results Available,Breast Cancer,,"May 4, 2020","Department of Gynecology and Obstetrics, University of Aachen, Aachen, Germany",https://ClinicalTrials.gov/show/NCT04373655
Study Director,"Pierre FUMOLEAU, PhD",Institut Curie,,NCT04327063,pierre fumoleau,pierre,male,0.99,91174,200,NCT04327063,MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery,Not yet recruiting,No Results Available,Malignant Neoplasm of Breast,Drug: Saline|Drug: Ropivacaine,"March 30, 2020","Centre Jean Perrin, Clermont-Ferrand, France|Institut Curie, Paris, France|Hopital Tenon, Paris, France",https://ClinicalTrials.gov/show/NCT04327063
Principal Investigator,"Margaret E Gatti-Mays, M.D.",National Cancer Institute (NCI),,NCT04296942,margaret e gatti-mays,margaret,female,0.99,17172,201,NCT04296942,"BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)",Not yet recruiting,No Results Available,Breast Cancer|Triple Negative Breast Cancer|HER2+ Breast Cancer|Hormone Receptor Negative Breast Cancer|Metastatic Breast Cancer,Biological: Brachyury-TRICOM|Drug: Entinostat|Biological: M7824|Biological: Ado-trastuzumab emtansine,"March 5, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04296942
Principal Investigator,"Margaret Barton-Burke, PhD, RN",Memorial Sloan Kettering Cancer Center,,NCT04216576,margaret barton-burke,margaret,female,0.99,17172,255,NCT04216576,A Study of the Use of Text Message Reminders to Take Palbociclib,Recruiting,No Results Available,Breast Cancer,Other: Paper Drug Diary|Other: OhMD APP,"January 2, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04216576
Principal Investigator,Jieqiong Liu,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,,NCT04303741,jieqiong liu,jieqiong,female,1.0,5,205,NCT04303741,A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC,Recruiting,No Results Available,Breast Cancer,Drug: Camrelizumab|Drug: Apatinib|Drug: Eribulin,"March 11, 2020","The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China",https://ClinicalTrials.gov/show/NCT04303741
Principal Investigator,"Joyce O'Shaughnessy, MD",Texas Oncology,,NCT04265872,joyce o'shaughnessy,joyce,female,0.96,16082,206,NCT04265872,Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC,Not yet recruiting,No Results Available,Breast Cancer,Drug: Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis,"February 12, 2020","Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States",https://ClinicalTrials.gov/show/NCT04265872
Study Director,"BLEUSE JEAN-PIERRE, DR",ICM Val d'Aurelle DRCI,,NCT04414202,bleuse jean-pierre,bleuse,female,0.58,12,208,NCT04414202,Observational Study of Intra-operative Partial Irradiation of Invasive Ductal Breast Carcinomas With a Good Prognosis,Recruiting,No Results Available,Invasive Breast Cancer|Breast-conserving Surgery,Procedure: tumorectomy with axillary dissection (sentinel lymph node)|Radiation: per-operative partial irradiation,"June 4, 2020","Icm Val D'Aurelle, Montpellier, Herault, France",https://ClinicalTrials.gov/show/NCT04414202
Principal Investigator,"Silje E Reme, PhD",Oslo University Hospital,,NCT04300283,silje e reme,silje,female,0.98,401,213,NCT04300283,Pre-operative Hypnosis to Prevent Side Effects After Surgery,Recruiting,No Results Available,Breast Cancer Surgery,Behavioral: Hypnosis,"March 9, 2020","Oslo University Hospital, Oslo, Norway",https://ClinicalTrials.gov/show/NCT04300283
Principal Investigator,YEON HEE PARK,Samsung Medical Center,,NCT04368442,yeon hee park,yeon,female,0.68,761,214,NCT04368442,Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation,Recruiting,No Results Available,Breast Cancer Metastatic,,"April 29, 2020","Samsung Medical Center, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04368442
Study Director,"Elaina Gartner, MD",Zymeworks Inc.,,NCT04224272,elaina gartner,elaina,female,0.98,98,217,NCT04224272,A Study of ZW25 With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,Recruiting,No Results Available,HER2+/HR+ Breast Cancer,Drug: ZW25|Drug: Palbociclib|Drug: Fulvestrant,"January 13, 2020","Sarah Cannon Research Institute, Nashville, Tennessee, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain",https://ClinicalTrials.gov/show/NCT04224272
Principal Investigator,Timothy Whelan,"Juravinski Cancer Centre, McMaster University, Hamilton",,NCT04228991,timothy whelan,timothy,male,0.99,13105,218,NCT04228991,Hypofractionated LocoRegional Radiotherapy in Breast Cancer,Not yet recruiting,No Results Available,Breast Neoplasms|Radiotherapy|Lymphedema,Radiation: Locoregional radiation treatment - Conventional fractionation|Radiation: Locoregional radiation treatment - Hypofractionation,"January 14, 2020","Juravinski Cancer Centre, Hamilton, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04228991
Principal Investigator,"Ann H Partridge, MD",Dana-Farber Cancer Institute,,NCT04379414,ann h partridge,ann,female,0.97,28026,219,NCT04379414,YES Study - Newly Diagnosed/Metastatic Intervention,Not yet recruiting,No Results Available,"Breast Cancer|Symptom, Behavioral",Behavioral: YES portal,"May 7, 2020","Dana Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04379414
Study Director,"Niklas Loman, MD, PhD",Lund University Hospital,,NCT04335669,niklas loman,niklas,male,1.0,10027,222,NCT04335669,"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC",Recruiting,No Results Available,Breast Cancer|Triple Negative Breast Neoplasms,"Drug: epirubicin, cyclophosphamide, paclitaxel, carboplatin|Drug: epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin","April 6, 2020","Södra Älvsborgs Hospital, Borås, Sweden|Gävle hospital, Department of Oncology, Gävle, Sweden|Sahlgrenska University Hospital, Department of Oncology, Göteborg, Sweden|Halmstad Hospital, Department of Surgery, Halmstad, Sweden|Ryhov Hospital, Jönköping, Sweden|Karlstad Hospital, Karlstad, Sweden|Linköping University Hospital, Linköping, Sweden|Skåne University Hospital, Department of Oncology, Malmö, Sweden|Capio S:t Göran Hospital, Department of Oncology, Stockholm, Sweden|Södersjukhuset, Department of Oncology, Stockholm, Sweden|Sundsvall hospital, Sundsvall, Sweden|Norrland University Hospital, Department of Oncology, Umeå, Sweden|Academical Hospital, Department of Oncology, Uppsala, Sweden|Västmanlands Hopsital Västerås, Västerås, Sweden|Växjö Hospital, Department of Oncology, Växjö, Sweden|Örebro University Hospital, Department of Oncology, Örebro, Sweden",https://ClinicalTrials.gov/show/NCT04335669
Study Director,"Manuel Gaviria, MD, PhD",Alliance Equiphoria,,NCT04350398,manuel gaviria,manuel,male,0.99,166605,223,NCT04350398,Rehabilitation Through Hippotherapy for the Management of Women After Primary Treatment of Breast Cancer,Recruiting,No Results Available,Breast Cancer Female|Side Effects|Psychological Distress|Physical Disability,Other: Hippotherapy|Other: Conventional therapy,"April 17, 2020","Institut Equiphoria, La Canourgue, France",https://ClinicalTrials.gov/show/NCT04350398
Principal Investigator,Ciara C O'Sullivan,Academic and Community Cancer Research United,,NCT04351230,ciara c o'sullivan,ciara,female,0.97,2003,225,NCT04351230,Abemaciclib With or Without T-DM1 for the Treatment of HER2-Positive Metastatic Breast Cancer,Not yet recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,Drug: Abemaciclib|Biological: Trastuzumab Emtansine,"April 17, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois, United States|Ochsner NCI Community Oncology Research Program, New Orleans, Louisiana, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04351230
Principal Investigator,Mina S Sedrak,City of Hope Medical Center,,NCT04305834,mina s sedrak,mina,female,0.91,20051,226,NCT04305834,Abemaciclib Monotherapy in Treating Older Patients With Hormone Receptor Positive Metastatic Breast Cancer,Recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,Drug: Abemaciclib|Other: Questionnaire Administration,"March 12, 2020","City of Hope Medical Center, Duarte, California, United States",https://ClinicalTrials.gov/show/NCT04305834
Principal Investigator,"Elaine Guirro, PhD",University of Sao Paulo - Ribeirao Preto - Brazil,,NCT04303221,elaine guirro,elaine,female,0.98,8901,228,NCT04303221,Effects of the Anchor System in the Postural Stability,Recruiting,No Results Available,Breast Cancer|Balance; Distorted,Other: Exercise,"March 11, 2020","Medical School of Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil",https://ClinicalTrials.gov/show/NCT04303221
Study Chair,"Maya Said, Sci.D",Outcomes4Me,,NCT04262518,maya said,maya,female,0.95,22722,229,NCT04262518,Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer|Invasive Breast Cancer|Metastatic Breast Cancer|Breast Carcinoma|Metastatic Breast Carcinoma,Device: Outcomes4Me Mobile App,"February 10, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04262518
Principal Investigator,"Pavani Chalasani, MD",University of Arizona,,NCT04291950,pavani chalasani,pavani,female,0.9,51,230,NCT04291950,Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women,Not yet recruiting,No Results Available,Triple Negative Breast Cancer,Procedure: Needle core biopsy,"March 2, 2020","University of Arizona Cancer Center, Tucson, Arizona, United States",https://ClinicalTrials.gov/show/NCT04291950
Principal Investigator,Shipra Gandhi,Roswell Park Cancer Institute,,NCT04348747,shipra gandhi,shipra,female,0.99,88,231,NCT04348747,"Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer",Not yet recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Malignant Neoplasm in the Brain|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,Biological: Anti-HER2/HER3 Dendritic Cell Vaccine|Drug: Celecoxib|Biological: Pembrolizumab|Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod,"April 16, 2020","Roswell Park Cancer Institute, Buffalo, New York, United States",https://ClinicalTrials.gov/show/NCT04348747
Principal Investigator,"Elisabetta Rossi, MD",European Institute of Oncology,,NCT04365803,elisabetta rossi,elisabetta,female,0.99,12887,234,NCT04365803,Histology VABB-Histology Post Surgery Pilot Project (BETTY Trial),Recruiting,No Results Available,Breast Cancer,Procedure: vacuum-assisted breast biopsy,"April 28, 2020","European Instituto of Oncology, Milan, Italy",https://ClinicalTrials.gov/show/NCT04365803
Principal Investigator,"Carol J Fabian, MD",University of Kansas Medical Center,,NCT04379024,carol j fabian,carol,female,0.97,33721,235,NCT04379024,Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms,Recruiting,No Results Available,Focus of Study is Healthy Women at Risk for Breast Cancer,Drug: DUAVEE 0.45Mg-20Mg Tablet,"May 7, 2020","University of Kansas Medical Center, Kansas City, Kansas, United States",https://ClinicalTrials.gov/show/NCT04379024
Principal Investigator,Stephen B Edge,Roswell Park Cancer Institute,,NCT04297384,stephen b edge,stephen,male,0.99,36980,236,NCT04297384,Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice,Recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma,Other: Informational Intervention|Other: Quality-of-Life Assessment|Other: Survey Administration,"March 5, 2020","Roswell Park Cancer Institute, Buffalo, New York, United States",https://ClinicalTrials.gov/show/NCT04297384
Principal Investigator,"Gabriele Martelli, MD","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",,NCT04436809,gabriele martelli,gabriele,male,0.85,34408,237,NCT04436809,Sentinel Node Biopsy Alone or With Axillary Dissection After Primary Chemotherapy,Completed,No Results Available,Breast Neoplasm Female,Procedure: Sentinel Node Biopsy|Procedure: Axillary Dissection,"June 18, 2020",,https://ClinicalTrials.gov/show/NCT04436809
Principal Investigator,Alicia Okines,The Royal Marsden Hospital,,NCT04360941,alicia okines,alicia,female,0.98,41386,238,NCT04360941,PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer,Not yet recruiting,No Results Available,Triple Negative Breast Cancer|Locally Advanced Breast Cancer|Recurrent Breast Cancer|Metastatic Breast Cancer|ER+ Breast Cancer|HER2-positive Breast Cancer,Drug: Palbociclib|Drug: Avelumab,"April 24, 2020","Royal Marsden NHS Foundation Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04360941
Principal Investigator,"Ana Lohmann, MD, PhD",London Regional Cancer Program,,NCT04241237,ana lohmann,ana,female,0.98,273767,240,NCT04241237,Concordance Between Liquid and Tissue Biopsy,Not yet recruiting,No Results Available,Breast Neoplasms,Procedure: Blood Draw,"January 27, 2020","London Regional Cancer Program, London, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04241237
Principal Investigator,Mridula A George,Rutgers Cancer Institute of New Jersey,,NCT04445844,mridula a george,mridula,female,0.93,29,243,NCT04445844,"INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study",Not yet recruiting,No Results Available,Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Triple-negative Breast Cancer,Biological: Pelareorep|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Biological: Retifanlimab,"June 24, 2020","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",https://ClinicalTrials.gov/show/NCT04445844
Principal Investigator,"Ritesh Parajuli, MD",Chao Family Comprehensive Cancer Center,,NCT04305236,ritesh parajuli,ritesh,male,0.99,1096,244,NCT04305236,Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer,Not yet recruiting,No Results Available,Breast Neoplasm|Hormone Receptor Positive Breast Carcinoma,Drug: Abemaciclib|Drug: Fulvestrant,"March 12, 2020","Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States",https://ClinicalTrials.gov/show/NCT04305236
Study Director,Sebahat GÖZÜM,Akdeniz University,,NCT04304404,sebahat gözüm,sebahat,female,0.96,1009,245,NCT04304404,Risk Reduction Program for Women Having High Risk of Breast Cancer,"Active, not recruiting",No Results Available,Cancer Screening|Early Detection of Cancer|Breast Cancer|Preventive Health Care|Health Behavior,Behavioral: Breast Cancer Risk Reduction Program,"March 11, 2020","Akdeniz University, Antalya, Turkey",https://ClinicalTrials.gov/show/NCT04304404
Principal Investigator,"Ian E Krop, MD, PHD",Dana-Farber Cancer Institute,,NCT04425018,ian e krop,ian,male,0.99,27117,246,NCT04425018,MARGetuximab Or Trastuzumab (MARGOT),Not yet recruiting,No Results Available,Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|HER2-positive Breast Cancer,Drug: Paclitaxel|Drug: Pertuzumab|Drug: Margetuximab|Drug: Trastuzumab,"June 11, 2020","Dana Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04425018
Principal Investigator,Ian E Krop,ECOG-ACRIN Cancer Research Group,,NCT04439175,ian e krop,ian,male,0.99,27117,390,NCT04439175,Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I),"Active, not recruiting",No Results Available,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma,Drug: Taselisib,"June 19, 2020","ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04439175
Principal Investigator,Galina Velikova,University of Leeds,,NCT04270123,galina velikova,galina,female,0.99,7539,247,NCT04270123,An EORTC Study Updating the QLQ-BR23 to BR45,Not yet recruiting,No Results Available,Cancer|Breast Cancer,Other: EORTC QLQ-BR45 questionnaire,"February 17, 2020","Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04270123
Principal Investigator,Laura Kenny,Imperial College London,,NCT04276272,laura kenny,laura,female,0.98,288403,248,NCT04276272,D4 Choline Breast PET/CT,Not yet recruiting,No Results Available,HER2-negative Breast Cancer|ER Positive Breast Cancer|Metastatic Breast Cancer,Other: Imaging scan,"February 19, 2020","Imperial College Healthcare NHS Trust/ Imperial College london, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04276272
Principal Investigator,"Sara C Tolaney, MD, MPH",Dana-Farber Cancer Institute,,NCT04448886,sara c tolaney,sara,female,0.98,244324,249,NCT04448886,Sacituzumab Govitecan Vs Pembrolizumab In HR+ / HER2 - MBC,Not yet recruiting,No Results Available,Invasive Breast Cancer|Metastatic Breast Cancer|HR-Positive Breast Cancer|HER2-negative Breast Cancer,Drug: Pembrolizumab|Drug: Sacituzumab Govitecan,"June 26, 2020","Dana Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04448886
Principal Investigator,"Mary Beth Terry, PhD",Columbia University,,NCT04265547,mary beth terry,mary,female,0.99,142684,250,NCT04265547,Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition,Enrolling by invitation,No Results Available,Breast Cancer Risk,Behavioral: Breast Cancer Risk Reduction Household Intervention,"February 11, 2020","Columbia University Mailman School of Public Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04265547
Principal Investigator,"Mary L. (Nora) Disis, MD",UW Medicine Seattle,,NCT04246671,mary l. (nora) disis,mary,female,0.99,142684,374,NCT04246671,Phase 1/2 Trial of Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients,Not yet recruiting,No Results Available,Breast Cancer|Gastric Cancer|Cancer,Biological: TAEK-VAC-HerBy,"January 29, 2020",,https://ClinicalTrials.gov/show/NCT04246671
Study Director,"Timo Schinköthe, PhD",Cankado Service GmbH,,NCT04386629,timo schinköthe,timo,male,0.99,16048,251,NCT04386629,Health Economy Register,Recruiting,No Results Available,Breast Neoplasms,,"May 13, 2020","Hämato-onkologischer Studienkreis am Klinikum Aschaffenburg, Aschaffenburg, Germany|Kliniken der Stadt Köln - Krankenhaus Holweide, Brustzentrum, Cologne, Germany|Kliniken Essen Mitte, Essen, Germany|Onkology Bethanien Frankfurt, Frankfurt, Germany|Mammazentrum Hamburg Am Krankenhaus Jerusalem, Hamburg, Germany|University Hospital, Mainz, Germany|University Hospital, Mannheim, Germany|University Hospital, München, Germany|Johanna Etienne Krankenhaus, Neuss, Germany|Praxisnetzwerk Hämatologie/ intern. Onkologie, Troisdorf, Germany",https://ClinicalTrials.gov/show/NCT04386629
Principal Investigator,"Alper Tuğral, PT","Bakırçay University, Fac. of Health Sci, Dept. of Physical Therapy and Rehab",,NCT04245657,alper tuğral,alper,male,0.97,21857,253,NCT04245657,Factors Affecting Functionality in Breast Cancer Survivors,Recruiting,No Results Available,"Breast Cancer|Breast Cancer Female|Breast Cancer Lymphedema|Breast Carcinoma in Situ|Hand Grasp|Pain, Shoulder","Other: Tissue Dielectric Constant Measurement|Other: Muscle strength measurement|Other: Hand-Grip Strength Measurement|Other: Pain Threshold Measurement|Other: International Physical Activity Questionnaire-Short Form (IPAQ-SF)|Other: Fatigue Impact Scale|Other: Disabilities of Arm, Shoulder and Hand Scale (DASH)|Other: Exercise Benefits/ Barriers Scale|Other: Beck Depression Scale","January 29, 2020","İzmir Çiğli State Training Hospital, İzmir, Çiğli, Turkey",https://ClinicalTrials.gov/show/NCT04245657
Study Chair,"Céline BOURGIER, MD",Institut Régional du Cancer de Montpellier (ICM),,NCT04282122,céline bourgier,céline,female,1.0,10,254,NCT04282122,Clinical Database of Safe Personalized Adjuvant Breast Radiotherapy Based on Individual Radiosensitivity,Recruiting,No Results Available,Breast Cancer,Radiation: Radiotherapy,"February 24, 2020","Institut Régional du Cancer de Montpellier, Montpellier, Occ, France",https://ClinicalTrials.gov/show/NCT04282122
Principal Investigator,Saranya Chumsri,Mayo Clinic,,NCT04249622,saranya chumsri,saranya,female,0.98,446,256,NCT04249622,Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer,Not yet recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,Other: Best Practice|Other: Questionnaire Administration|Drug: Rifaximin,"January 31, 2020","Mayo Clinic in Florida, Jacksonville, Florida, United States",https://ClinicalTrials.gov/show/NCT04249622
Study Chair,Atilla Soran,University of Pittsburgh Medical Center,,NCT04272372,atilla soran,atilla,male,0.97,9445,257,NCT04272372,Lymphedema Treatment Registry,Not yet recruiting,No Results Available,Breast Cancer Lymphedema,Drug: Ketoprofen,"February 17, 2020",,https://ClinicalTrials.gov/show/NCT04272372
Principal Investigator,"Kathleen Van Dyk, PhD",University of California at Los Angeles,,NCT04297020,kathleen van dyk,kathleen,female,0.98,8685,260,NCT04297020,Brain Health in Breast Cancer Survivors,Recruiting,No Results Available,Cognitive Impairment|Cognitive Function,,"March 5, 2020","University of California at Los Angeles, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04297020
Principal Investigator,"Kathleen Arcaro, PhD","University of Massachusetts, Amherst",,NCT04374747,kathleen arcaro,kathleen,female,0.98,8685,275,NCT04374747,Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk,Recruiting,No Results Available,"Breast Cancer Female|Inflammation|Postpartum Weight Retention|Diet, Healthy|Risk Reduction",Behavioral: Dietary Counseling,"May 5, 2020","University of Massachusetts Amherst, Amherst, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04374747
Principal Investigator,"Lindiwe Sibeko, PhD","University of Massachusetts, Amherst",,NCT04374747,lindiwe sibeko,lindiwe,female,1.0,390,275,NCT04374747,Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk,Recruiting,No Results Available,"Breast Cancer Female|Inflammation|Postpartum Weight Retention|Diet, Healthy|Risk Reduction",Behavioral: Dietary Counseling,"May 5, 2020","University of Massachusetts Amherst, Amherst, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04374747
Principal Investigator,"Susan Sturgeon, DrPH","University of Massachusetts, Amherst",,NCT04374747,susan sturgeon,susan,female,0.98,32184,275,NCT04374747,Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk,Recruiting,No Results Available,"Breast Cancer Female|Inflammation|Postpartum Weight Retention|Diet, Healthy|Risk Reduction",Behavioral: Dietary Counseling,"May 5, 2020","University of Massachusetts Amherst, Amherst, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04374747
Principal Investigator,"Hyosuk Chin, MD",McMaster University,,NCT04306003,hyosuk chin,hyosuk,male,0.57,14,261,NCT04306003,ERAS in Autologous Breast Reconstruction: A Pilot RCT,Recruiting,No Results Available,Breast Cancer,Other: ERAS pathway|Other: Standard Perioperative Care,"March 12, 2020","Juravinski Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare, Hamilton, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04306003
Principal Investigator,"Marko Simunovic, MD",Hamilton Health Sciences Corporation,,NCT04306003,marko simunovic,marko,male,0.99,32295,261,NCT04306003,ERAS in Autologous Breast Reconstruction: A Pilot RCT,Recruiting,No Results Available,Breast Cancer,Other: ERAS pathway|Other: Standard Perioperative Care,"March 12, 2020","Juravinski Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare, Hamilton, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04306003
Study Director,Novartis Pharmaceuticals,Novartis Pharmaceuticals,,NCT04251533,novartis pharmaceuticals,novartis,male,1.0,4,262,NCT04251533,Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation,Recruiting,No Results Available,Triple Negative Breast Neoplasms,Drug: alpelisib|Drug: placebo|Drug: nab-paclitaxel,"February 5, 2020","Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04251533
Principal Investigator,"Michelle P Judge, PhD",University of Connecticut,,NCT04293874,michelle p judge,michelle,female,0.98,66334,265,NCT04293874,Adaptive Symptom Care Using Fish-Based Nutritional Directives Post Breast Cancer,Suspended,No Results Available,Fatigue|Depression|Pain|Sleep Disturbance|Stress|Survivorship|Breast Cancer|Dietary Habits,Behavioral: Personalized Meal Plan|Behavioral: Dietary Omega-3LC intervention,"March 3, 2020","Hartford HealthCare Cancer Institue, Hartford, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04293874
Principal Investigator,"Michelle Coriddi, MD",Memorial Sloan Kettering Cancer Center,,NCT04241341,michelle coriddi,michelle,female,0.98,66334,279,NCT04241341,Does Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection,Recruiting,No Results Available,Breast Cancer Lymphedema,Procedure: Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction|Procedure: Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction|Other: quality-of-life questionnaires|Other: measured by arm volume,"January 27, 2020","Memoral Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States|Memoral Sloan Kettering Westchester (Consent Only), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau (Consent only), Uniondale, New York, United States",https://ClinicalTrials.gov/show/NCT04241341
Principal Investigator,"Gareth Evans, MD",Manchester University NHS Foundation Trust,,NCT04359420,gareth evans,gareth,male,0.99,5276,266,NCT04359420,What Are the Benefits and Harms of Risk Stratified Screening in the NHS Breast Screening Programme: Study Protocol,"Active, not recruiting",No Results Available,Breast Cancer,Other: BC-Predict|Other: NHS Breast Screening Programme,"April 24, 2020","Manchester University NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom",https://ClinicalTrials.gov/show/NCT04359420
Principal Investigator,"Victoire BRILLAUD-MEFLAH, MD",Institut de Cancérologie de l'Ouest,,NCT04343820,victoire brillaud-meflah,victoire,female,0.93,1976,267,NCT04343820,Delayed Breast Reconstruction by Prepectoral Implant After Lipo-preparation (RM2prepec),Recruiting,No Results Available,Breast Cancer Female,Procedure: Breast reconstruction,"April 13, 2020","Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France",https://ClinicalTrials.gov/show/NCT04343820
Principal Investigator,Victoire BRILLAUD-MEFLAH,Institut de Cancerologie de l'Ouest,,NCT04329819,victoire brillaud-meflah,victoire,female,0.93,1976,285,NCT04329819,Satisfaction and QUality of Life After Breast REconstruction,Completed,No Results Available,Mammaplasty|Breast Neoplasm Female,,"April 1, 2020","Institut de Cancerologie de l'Ouest, Saint-Herblain, France",https://ClinicalTrials.gov/show/NCT04329819
Principal Investigator,Tufia C Haddad,Mayo Clinic,,NCT04294225,tufia c haddad,tufia,female,0.5,2,268,NCT04294225,Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer,Recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,Drug: Anastrozole|Drug: Letrozole,"March 4, 2020","Mayo Clinic, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04294225
Principal Investigator,Emmanuel M Gabriel,Mayo Clinic,,NCT04249167,emmanuel m gabriel,emmanuel,male,0.99,45589,269,NCT04249167,"Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer",Recruiting,No Results Available,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8,Drug: Atezolizumab|Procedure: Cryosurgery|Drug: Nab-paclitaxel,"January 30, 2020","Mayo Clinic in Florida, Jacksonville, Florida, United States",https://ClinicalTrials.gov/show/NCT04249167
Study Director,"Ariane SULTAN, PR","University Hospital, Montpellier",,NCT04357652,ariane sultan,ariane,female,0.97,5286,270,NCT04357652,Contraception and Cervical and Breast Cancer Screening in Obese Versus Non-obese Women,Not yet recruiting,No Results Available,Obesity,,"April 22, 2020","Uhmontpellier, Montpellier, France",https://ClinicalTrials.gov/show/NCT04357652
Principal Investigator,Nusayba Bagegni,Duke University - Duke Cancer Institute LAO,,NCT04345913,nusayba bagegni,nusayba,female,0.5,2,271,NCT04345913,Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer,Not yet recruiting,No Results Available,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Breast Carcinoma,Drug: Copanlisib Hydrochloride|Drug: Eribulin Mesylate,"April 15, 2020",,https://ClinicalTrials.gov/show/NCT04345913
Principal Investigator,"Faisal Shamim, FCPS",Aga Khan University,,NCT04343807,faisal shamim,faisal,male,0.98,12681,272,NCT04343807,Ultrasound Guided PECS Block for Reducing Opioid Consumption and Improving Patient Satisfaction Through Adequate Pain Control Following Breast Cancer Surgery.,Not yet recruiting,No Results Available,"Breast Neoplasm Female|Pain, Postoperative|Pain|Analgesia|Anaesthesia|Breast Cancer",Procedure: PECS Block|Other: Control Group,"April 13, 2020",,https://ClinicalTrials.gov/show/NCT04343807
Study Director,WEN-HSUAN HOU,Taipei Medical University,,NCT04378816,wen-hsuan hou,wen-hsuan,female,0.5,2,273,NCT04378816,A Patient-centered Continuous and Interdisciplinary Shared Decision Making Approach for Breast Cancer Rehabilitation,Recruiting,No Results Available,Shared Decision Making|Self-Efficacy for Decision Making,Other: Shared decision making support tool,"May 7, 2020","Taipei Medical University Hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04378816
Principal Investigator,"Susan Dent, MD",Duke University,,NCT04330625,susan dent,susan,female,0.98,32184,303,NCT04330625,Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477),Not yet recruiting,No Results Available,Hyperglycemia Drug Induced,Biological: REMD-477,"April 1, 2020",,https://ClinicalTrials.gov/show/NCT04330625
Principal Investigator,"Ilkka Heinonen, PhD",staff,,NCT04416087,ilkka heinonen,ilkka,male,1.0,597,277,NCT04416087,Exercise and Tumor Blood Flow in Breast Cancer Patients,Recruiting,No Results Available,"Cancer, Breast",Other: Exercise,"June 4, 2020","Turku PET Centre, Turku, Finland",https://ClinicalTrials.gov/show/NCT04416087
Principal Investigator,"Aditya Bardia, MD, MPH",Massachusetts General Hospital,,NCT04230109,aditya bardia,aditya,male,0.98,3231,278,NCT04230109,Sacituzumab Govitecan In TNBC,Not yet recruiting,No Results Available,Invasive Breast Cancer|Triple Negative Breast Cancer|ER-Negative Breast Cancer|PR-Negative Breast Cancer|HER2-negative Breast Cancer,Drug: Sacituzumab Govitecan,"January 18, 2020","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital - North Shore Cancer Center, Danvers, Massachusetts, United States|Massachusetts General Hospital at Newton-Wellesley Hospital, Newton, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04230109
Study Director,"Vivian Li, MD",BeiGene,,NCT04276493,vivian li,vivian,female,0.92,11853,280,NCT04276493,Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab,Recruiting,No Results Available,Breast Cancer|Gastric Cancer|Gastroesophageal Junction Cancer,Biological: ZW25|Drug: Docetaxel|Biological: Tislelizumab|Drug: Capecitabine|Drug: Oxaliplatin,"February 19, 2020","National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul Saint Mary's Hospital, Seoul, Korea, Republic of|Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04276493
Principal Investigator,Janice Kiecolt-Glaser,Ohio State Comprehensive Cancer Center,,NCT04247763,janice kiecolt-glaser,janice,female,0.98,6277,283,NCT04247763,"Fast Food, Fatigue, and Inflammation",Completed,No Results Available,Breast Cancer,Other: Saturated Fat Meal|Other: Oleic Sunflower Oil Meal,"January 30, 2020","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",https://ClinicalTrials.gov/show/NCT04247763
Principal Investigator,"Lisa Cadmus-Bertram, Ph.D.","University of Wisconsin, Madison",,NCT04262180,lisa cadmus-bertram,lisa,female,0.98,102796,377,NCT04262180,Physical Activity Promotion for Breast and Endometrial Cancer Survivors,Not yet recruiting,No Results Available,Physical Activity|Breast Cancer Survivors|Endometrial Cancer Survivors,Other: Base intervention-Fitbit with EHR integration|Other: Coaching Calls|Other: Online Gym,"February 10, 2020","Department of Preventative Medicine, Northwestern University, Chicago, Illinois, United States|Department of Kinesiology, University of Wisconsin, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04262180
Principal Investigator,"Siobhan Phillips, Ph.D., MPH","Northwestern University, Chicago",,NCT04262180,siobhan phillips,siobhan,female,0.97,1398,377,NCT04262180,Physical Activity Promotion for Breast and Endometrial Cancer Survivors,Not yet recruiting,No Results Available,Physical Activity|Breast Cancer Survivors|Endometrial Cancer Survivors,Other: Base intervention-Fitbit with EHR integration|Other: Coaching Calls|Other: Online Gym,"February 10, 2020","Department of Preventative Medicine, Northwestern University, Chicago, Illinois, United States|Department of Kinesiology, University of Wisconsin, Madison, Wisconsin, United States",https://ClinicalTrials.gov/show/NCT04262180
Principal Investigator,"Daniel Cagney, MD",Dana-Farber Cancer Institute,,NCT04368702,daniel cagney,daniel,male,0.99,317409,291,NCT04368702,CONFIRM: Magnetic Resonance Guided Radiation Therapy,Not yet recruiting,No Results Available,Gastric Cancer|Invasive Breast Cancer|in Situ Breast Cancer,Radiation: Viewray MRIdian® Linac,"April 30, 2020","Brigham & Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04368702
Principal Investigator,"Marta Vaz Batista, MD",MedSIR,,NCT04420598,marta vaz batista,marta,female,0.98,184145,292,NCT04420598,"DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease","Active, not recruiting",No Results Available,Advanced Breast Cancer|HER2-positive Breast Cancer|Brain Metastases|Leptomeningeal Metastasis,Drug: Trastuzumab deruxtecan,"June 9, 2020","Champalimaud Center for the Unknown, Lisbon, Portugal|Hospital da Luz, Lisbon, Portugal|Hospital Fernando Fonseca, Lisbon, Portugal|Hospital Santa Maria-Centro Hospitalario Lisboa Norte, Lisbon, Portugal|Instituto Português de Oncologia do Porto Francisco Gentil, EPE (IPO Porto), Porto, Portugal|Institut Català d'Oncologica ICO Badalona, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Institut Oncologic Baselga-Hospital Quiron Salud Barcelona, Barcelona, Spain|Hospital San Pedro de Alcantara, Cáceres, Spain|Institut Catala d'Oncologia ICO Hospitalet, L'Hospitalet De Llobregat, Spain|Hospital Universitari Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|IOB- Complejo Hospitalario Ruber Juan Bravo, Madrid, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Consorcio Hospital General de Valencia, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario Migue Servet, Zaragoza, Spain",https://ClinicalTrials.gov/show/NCT04420598
Principal Investigator,"Bong-Jin Hahm, M.D.,Ph.D.",Seoul National University Hospital,,NCT04364347,bong-jin hahm,bong-jin,male,0.75,4,293,NCT04364347,Chemotherapy-induced Circadian Rhythm Disruption,Recruiting,No Results Available,Breast Neoplasms,,"April 28, 2020","Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04364347
Principal Investigator,"Elodie Demblocque, MD",CH Beauvais,,NCT04270136,elodie demblocque,elodie,female,0.98,55903,294,NCT04270136,Feasibility of Total Mastectomy in Ambulatory Care,Not yet recruiting,No Results Available,Breast Cancer|Mastectomy|Ambulatory Care,Procedure: total mastectomy,"February 17, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04270136
Principal Investigator,"Albine Mancaux, MD",CH Beauvais,,NCT04270136,albine mancaux,albine,female,0.88,107,294,NCT04270136,Feasibility of Total Mastectomy in Ambulatory Care,Not yet recruiting,No Results Available,Breast Cancer|Mastectomy|Ambulatory Care,Procedure: total mastectomy,"February 17, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04270136
Principal Investigator,"Pierrick Theret, MD",CH Saint Quentin,,NCT04270136,pierrick theret,pierrick,male,0.99,3653,294,NCT04270136,Feasibility of Total Mastectomy in Ambulatory Care,Not yet recruiting,No Results Available,Breast Cancer|Mastectomy|Ambulatory Care,Procedure: total mastectomy,"February 17, 2020","CHU Amiens, Amiens, France",https://ClinicalTrials.gov/show/NCT04270136
Principal Investigator,Nadine M Tung,ECOG-ACRIN Cancer Research Group,,NCT04266249,nadine m tung,nadine,female,0.98,55786,295,NCT04266249,CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy,Recruiting,No Results Available,Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8,Drug: Docetaxel|Procedure: Lumpectomy|Procedure: Mastectomy|Drug: Nab-paclitaxel|Drug: Paclitaxel|Biological: Pertuzumab|Radiation: Radiation Therapy|Biological: Trastuzumab|Biological: Trastuzumab Emtansine,"February 12, 2020","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Kingman Regional Medical Center, Kingman, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|PCR Oncology, Arroyo Grande, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Illinois CancerCare-Dixon, Dixon, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Genesis Cancer Center - Silvis, Silvis, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Genesis Medical Center - East Campus, Davenport, Iowa, United States|Genesis Cancer Care Institute, Davenport, Iowa, United States|Iowa Cancer Specialists, Davenport, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Maine Center for Cancer Medicine-Kennebunk, Kennebunk, Maine, United States|Maine Center for Cancer Medicine-Scarborough, Scarborough, Maine, United States|Maine Center for Cancer Medicine-Topsham, Topsham, Maine, United States|Beverly Hospital, Beverly, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, United States|Winchester Hospital, Winchester, Massachusetts, United States|Ascension Providence Hospitals - Novi, Novi, Michigan, United States|Ascension Providence Hospitals - Southfield, Southfield, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Parkland Health Center - Farmington, Farmington, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Las Vegas Urology - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pebble, Henderson, Nevada, United States|Urology Specialists of Nevada - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pecos, Las Vegas, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|OptumCare Cancer Care at Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Las Vegas Prostate Cancer Center, Las Vegas, Nevada, United States|Las Vegas Urology - Sunset, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Las Vegas Urology - Cathedral Rock, Las Vegas, Nevada, United States|Las Vegas Urology - Smoke Ranch, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Northwest, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Southwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, United States|New Hampshire Oncology Hematology PA-Hooksett, Hooksett, New Hampshire, United States|The Cancer Institute of New Jersey Hamilton, Hamilton, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States|Lovelace Medical Center-Saint Joseph Square, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Lovelace Women's Hospital, Albuquerque, New Mexico, United States|Presbyterian Kaseman Hospital, Albuquerque, New Mexico, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, United States|Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Wellmont Bristol Regional Medical Center, Bristol, Tennessee, United States|Regional Cancer Center at Indian Path Community Hospital, Kingsport, Tennessee, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas, United States|Doctor's Hospital of Laredo, Laredo, Texas, United States|UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas, United States|Wellmont Medical Associates-Bristol, Bristol, Virginia, United States|Bon Secours Memorial Regional Medical Center, Mechanicsville, Virginia, United States|Bon Secours Saint Francis Medical Center, Midlothian, Virginia, United States|Bon Secours DePaul Medical Center, Norfolk, Virginia, United States|Southwest VA Regional Cancer Center, Norton, Virginia, United States|Bon Secours Maryview Medical Center, Portsmouth, Virginia, United States|Bon Secours Saint Mary's Hospital, Richmond, Virginia, United States|Bon Secours Cancer Institute at Reynolds Crossing, Richmond, Virginia, United States|Bon Secours Health Center at Harbour View, Suffolk, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Valley Medical Center, Renton, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|ThedaCare Regional Cancer Center, Appleton, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",https://ClinicalTrials.gov/show/NCT04266249
Principal Investigator,William Gwin,Fred Hutch/University of Washington Cancer Consortium,,NCT04329065,william gwin,william,male,0.99,64097,296,NCT04329065,"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer",Not yet recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,Biological: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Drug: Paclitaxel|Biological: Trastuzumab|Biological: Pertuzumab,"April 1, 2020","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",https://ClinicalTrials.gov/show/NCT04329065
Principal Investigator,"William Eward, MD",Duke University,,NCT04389281,william eward,william,male,0.99,64097,373,NCT04389281,"X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma",Not yet recruiting,No Results Available,Advanced Cancer,Combination Product: X-PACT,"May 15, 2020",,https://ClinicalTrials.gov/show/NCT04389281
Principal Investigator,Carlos E Vargas,Mayo Clinic,,NCT04443413,carlos e vargas,carlos,male,0.99,236888,297,NCT04443413,Assessing the Rate of Complications in X-Ray Therapy Versus Proton Beam Radiation Therapy After Breast Conserving Surgery or Mastectomy in Treating Patients With Breast Cancer,Recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,Radiation: Proton Beam Radiation Therapy|Other: Questionnaire Administration|Radiation: X-ray Therapy,"June 23, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04443413
Study Director,Sandra PIQUIN,Insitut de Cancérologie de l'Ouest,,NCT04348955,sandra piquin,sandra,female,0.98,266121,298,NCT04348955,Interest of Touch-massage in Hospital Day Care,Recruiting,No Results Available,Breast Neoplasm Malignant Female,Behavioral: Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized,"April 16, 2020","Insitut de Cancérologie de l'Ouest, Angers, France|Insitut de Cancérologie de l'Ouest, Angers, France",https://ClinicalTrials.gov/show/NCT04348955
Principal Investigator,"Séverine RACADOT, MD",Centre Leon Berard,,NCT04300829,séverine racadot,séverine,female,0.99,134,300,NCT04300829,Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients,Not yet recruiting,No Results Available,Breast Adenocarcinoma|Radiation Dermatitis|Radiation Toxicity,Drug: cicaderma + simple hygiene rules|Other: Simple hygiene rules and a maximum of one topical treatment,"March 9, 2020","Institut Sainte-Catherine, Avignon, France|Institut Curie, Paris, France|Institut Curie, Saint-Cloud, France",https://ClinicalTrials.gov/show/NCT04300829
Principal Investigator,"Youlia KIROVA, MD PhD",Institut Curie,,NCT04300829,youlia kirova,youlia,female,1.0,52,300,NCT04300829,Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients,Not yet recruiting,No Results Available,Breast Adenocarcinoma|Radiation Dermatitis|Radiation Toxicity,Drug: cicaderma + simple hygiene rules|Other: Simple hygiene rules and a maximum of one topical treatment,"March 9, 2020","Institut Sainte-Catherine, Avignon, France|Institut Curie, Paris, France|Institut Curie, Saint-Cloud, France",https://ClinicalTrials.gov/show/NCT04300829
Principal Investigator,"Andrea Nisonson, MD",Prisma Health-Upstate,,NCT04251507,andrea nisonson,andrea,male,0.62,302977,301,NCT04251507,VR Ultrasound Guided Breast Localization,Not yet recruiting,No Results Available,Breast Neoplasm Female,Device: Oculus Go Virtual Reality Goggles,"February 5, 2020",,https://ClinicalTrials.gov/show/NCT04251507
Principal Investigator,"Carmelo Guido, MD",Careggi Hospital,,NCT04309929,carmelo guido,carmelo,male,0.99,18215,304,NCT04309929,Description of the Analgesia Obtained With the Anesthesiological Protocols Currently Used in Breast Surgery,Completed,No Results Available,Breast Cancer,Drug: Analgesics,"March 17, 2020","Azienda Ospedaliero Universitaria Careggi, Florence, Italy",https://ClinicalTrials.gov/show/NCT04309929
Principal Investigator,"Hugues Bourgeois, MD",Clinique Victor Hugo - LE MANS,,NCT04391543,hugues bourgeois,hugues,male,0.98,4738,305,NCT04391543,BIOpsychosocial Approach of the CAncer-RElated FAtigue (BIOCARE FActory),Not yet recruiting,No Results Available,Breast Cancer,Other: Experimental session,"May 18, 2020",,https://ClinicalTrials.gov/show/NCT04391543
Principal Investigator,"Kristina Ahsberg, PhD",Region Halland,,NCT04437602,kristina ahsberg,kristina,female,0.98,29132,306,NCT04437602,Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions,Not yet recruiting,No Results Available,Breast Cancer,Diagnostic Test: Contrast Enhanced Mammography (CEM),"June 18, 2020","Halland Hospital Halmstad, Halmstad, Sweden|Helsingborg Hospital, Helsingborg, Sweden|Central Hospital Kristianstad, Kristianstad, Sweden",https://ClinicalTrials.gov/show/NCT04437602
Principal Investigator,"John Ng, M.D.",Weill Cornell Medicine,,NCT04371913,john ng,john,male,0.99,218952,308,NCT04371913,Personalized Second Chance Breast Conservation (PSCBC): A Two Center Prospective Phase II Clinical Study,Recruiting,No Results Available,Breast Cancer,Radiation: 600cGY x 5 fractions,"May 1, 2020","Weill Cornell Medicine, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04371913
Study Director,"John Goldberg, MD","Oncorus, Inc.",,NCT04348916,john goldberg,john,male,0.99,218952,424,NCT04348916,"Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors",Recruiting,No Results Available,Cancer|Melanoma|Solid Tumor|Squamous Cell Carcinoma of Head and Neck|Breast Cancer|Advanced Solid Tumor,Biological: ONCR-177|Biological: pembrolizumab,"April 16, 2020","City of Hope, Duarte, California, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Sarah Cannon Research Institute - Tennessee Oncology, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04348916
Principal Investigator,John Marshall,Queen Mary University of London,,NCT04285996,john marshall,john,male,0.99,218952,427,NCT04285996,IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types,"Active, not recruiting",No Results Available,Cancer,Procedure: PET Scan,"February 26, 2020","Barts Health NHS Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04285996
Principal Investigator,Peter Schmid,Queen Mary University of London,,NCT04285996,peter schmid,peter,male,0.99,165452,427,NCT04285996,IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types,"Active, not recruiting",No Results Available,Cancer,Procedure: PET Scan,"February 26, 2020","Barts Health NHS Trust, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04285996
Principal Investigator,"Claire Conley, PhD",Moffitt Cancer Center,,NCT04257474,claire conley,claire,female,0.97,42044,311,NCT04257474,Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk,Recruiting,No Results Available,Breast Cancer,Behavioral: Self-Report Survey|Behavioral: Qualitative Interviews,"February 6, 2020","Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Moffitt Cancer Center, Tampa, Florida, United States",https://ClinicalTrials.gov/show/NCT04257474
Principal Investigator,"Manja Jensen, MD","Section of General Practice, University of Copenhagen",,NCT04424758,manja jensen,manja,female,0.95,1279,314,NCT04424758,Testing Video Information About Mammography Screening,Recruiting,No Results Available,Breast Cancer,Other: Video information about mammography screening|Other: Video information about smart energy systems,"June 11, 2020","University of Copenhagen, Section of General Practice, Copenhagen, Capital, Denmark",https://ClinicalTrials.gov/show/NCT04424758
Principal Investigator,"Deepa Sheth, MD",University of Chicago Medicine,,NCT04341129,deepa sheth,deepa,female,0.93,592,364,NCT04341129,Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine),Not yet recruiting,No Results Available,Breast Neoplasms|Breast Diseases|Breast Fibroadenoma|Breast Cancer,Drug: Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine),"April 10, 2020",,https://ClinicalTrials.gov/show/NCT04341129
Principal Investigator,"Lynn Henry, MD, PhD",University of Michigan Rogel Cancer Center,,NCT04268134,lynn henry,lynn,female,0.93,7857,318,NCT04268134,Altering Lipids for Tolerance of Aromatase Inhibitor Therapy,Not yet recruiting,No Results Available,Breast Cancer,Dietary Supplement: Omega-3 fatty acid supplement,"February 13, 2020","University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States",https://ClinicalTrials.gov/show/NCT04268134
Principal Investigator,"Khadra M Ali, Phd","Cairo University, Faculty of physical Therapy.",,NCT04257643,khadra m ali,khadra,female,0.94,168,320,NCT04257643,Aquatic Versus Land Based Exercise on Lymphedema Post Mastectomy,Completed,No Results Available,Breast Cancer,Other: aquatic based exercise.|Other: land-based exercise.,"February 6, 2020","Cairo university., Cairo., Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04257643
Principal Investigator,"Mona R Elghamry, MD","Tanta University, Faculty of Medicine",,NCT04239716,mona r elghamry,mona,female,0.97,20027,321,NCT04239716,Regional Anesthesia for Modified Radical Mastectomy With Axillary Lymph Node Dissection,Recruiting,No Results Available,Breast Cancer,Other: regional anesthesia,"January 27, 2020","Tanta University, Faculty of Medicine, Tanta, Egypt",https://ClinicalTrials.gov/show/NCT04239716
Study Director,"Mohamed E Afandy, MD","Tanta University, Faculty of Medicine",,NCT04239716,mohamed e afandy,mohamed,male,0.98,175927,321,NCT04239716,Regional Anesthesia for Modified Radical Mastectomy With Axillary Lymph Node Dissection,Recruiting,No Results Available,Breast Cancer,Other: regional anesthesia,"January 27, 2020","Tanta University, Faculty of Medicine, Tanta, Egypt",https://ClinicalTrials.gov/show/NCT04239716
Principal Investigator,Mohamed A Elbaiomy,Mansoura university Oncology Center,,NCT04274504,mohamed a elbaiomy,mohamed,male,0.98,175927,335,NCT04274504,Osteopontin in Metastatic Breast Cancer Patients,Completed,No Results Available,"Survival, Prosthesis",Diagnostic Test: Osteopontin,"February 18, 2020","Mansoura University Oncology Center, Mansoura, Daqahliyah, Egypt",https://ClinicalTrials.gov/show/NCT04274504
Principal Investigator,"Linda Koehler, PhD, PT, CLT-LANA","University of Minnesota, Division of Physical Therapy",,NCT04225572,linda koehler,linda,female,0.98,99198,322,NCT04225572,Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT),Recruiting,No Results Available,Breast Cancer,Behavioral: Physical Therapy: Dependent on Patient's Needs,"January 13, 2020","University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States",https://ClinicalTrials.gov/show/NCT04225572
Study Chair,"Katherine E. Reeder-Hayes, MD","University of North Carolina, Chapel Hill",,NCT04379570,katherine e. reeder-hayes,katherine,female,0.98,8451,324,NCT04379570,Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy,Not yet recruiting,No Results Available,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2 Negative Breast Carcinoma|Hormone Receptor Positive Breast Carcinoma|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8,Other: Educational Intervention|Other: Text Message-based Navigation Intervention|Behavioral: Motivational Interviewing|Other: Best Practice|Other: Questionnaire Administration|Other: Quality-of-Life Assessment,"May 7, 2020",,https://ClinicalTrials.gov/show/NCT04379570
Principal Investigator,"Cristian Ochoa, PhD","Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain, 08908",,NCT04372459,cristian ochoa,cristian,male,0.99,75120,325,NCT04372459,"Online Psychosocial Cancer Screening, Monitoring and Stepped Treatment in Cancer Survivors",Not yet recruiting,No Results Available,Breast Cancer|Psychological Distress|Emotional Disorder,Behavioral: Online integrated and stepped psychosocial care|Behavioral: Usual psychosocial care,"May 4, 2020",,https://ClinicalTrials.gov/show/NCT04372459
Principal Investigator,"Mathias Fehr, Prof. Dr.","Brustzentrum Thurgau, Kantonsspital Frauenfeld",,NCT04390529,mathias fehr,mathias,male,0.99,17180,326,NCT04390529,Immediate Breast Reconstruction Following Mastectomy (IRMA),Recruiting,No Results Available,Breast Cancer Female,Other: quality-of-life questionnaire: BREAST-Q,"May 15, 2020","Kantonsspital Baden, PD Dr. med. Cornelia Leo, Baden, Aargau, Switzerland|Tumor- und Brustzentrum ZeTuP, Dr. Véronique Dupont Lampert, St. Gallen, Saint Gallen, Switzerland|Kantonsspital Frauenfeld, Prof. Dr. med. Mathias K. Fehr, Frauenfeld, Thurgau, Switzerland|Ospedale Regionale Bellinzona e Valli, Dr. Begoña Lipp von Wattenwyl, Bellinzona, Ticino, Switzerland|Campus SLB Sonnenhof AG, Bern, Switzerland|Universitätsspital Zürich, Klinik für Gynäkologie, Zürich, Switzerland",https://ClinicalTrials.gov/show/NCT04390529
Principal Investigator,"Savitri Krishnamurthy, MD",M.D. Anderson Cancer Center,,NCT04242277,savitri krishnamurthy,savitri,female,0.95,85,327,NCT04242277,Wide-field Optical Coherence Tomography Imaging of Excised Breast Tissue.,Not yet recruiting,No Results Available,Breast Cancer Female,Device: Investigational WF-OCT device,"January 27, 2020","MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04242277
Principal Investigator,"Aiping Shi, Doctor",First Hospital of Jilin University,,NCT04440683,aiping shi,aiping,female,0.53,15,328,NCT04440683,Antler Plate on Preventing Mammary High-risk Lesions From Malignant Development,Recruiting,No Results Available,Breast Cancer Prevention,,"June 22, 2020","First Hospital of Jilin University, Changchun, Jilin, China",https://ClinicalTrials.gov/show/NCT04440683
Principal Investigator,"Richard J Barth Jr., MD",DHMC,,NCT04257799,richard j barth jr.,richard,male,0.99,101928,329,NCT04257799,Lumpectomy Specimen Margin Evaluation With Tomography and Structured Light Imaging,Recruiting,No Results Available,Breast Cancer Female,Other: Structured Light Imaging (SLI) System,"February 6, 2020","Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States",https://ClinicalTrials.gov/show/NCT04257799
Principal Investigator,"Cesar Santa-Maria, MD",Johns Hopkins University,,NCT04447651,cesar santa-maria,cesar,male,0.98,27863,330,NCT04447651,Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM),Not yet recruiting,No Results Available,Metastatic Breast Cancer|SF3B1 Gene Mutation|Spliceosome Mutation,Other: Recommendation for treatment with immunotherapy,"June 25, 2020",,https://ClinicalTrials.gov/show/NCT04447651
Principal Investigator,"Yi Feng, MD,PhD",Peking University People's Hospital,,NCT04390698,yi feng,yi,female,0.5,2044,336,NCT04390698,Opioid Free Anesthesia in Breast Cancer Surgery,Not yet recruiting,No Results Available,Opioid Free Anesthesia,Procedure: paravertebral block|Drug: opioid free anesthesia|Procedure: sham block|Procedure: opioid general anesthesia,"May 15, 2020",,https://ClinicalTrials.gov/show/NCT04390698
Principal Investigator,"walaa Y Elsabeeny, MD",Lecturer,,NCT04248608,walaa y elsabeeny,walaa,female,0.8,783,337,NCT04248608,Perioperative Analgesic Modalities for Breast Cancer Surgeries,Recruiting,No Results Available,Analgesia,Procedure: serratus plane block|Procedure: erector spinae block|Drug: Morphine Sulfate,"January 30, 2020","Department of anesthesia and pain medicine. National Cancer Institute, Cairo, Egypt",https://ClinicalTrials.gov/show/NCT04248608
Study Director,"Justine Walker, MD","Turnstone Biologics, Corp.",,NCT04301011,justine walker,justine,female,0.95,25925,338,NCT04301011,"Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors",Recruiting,No Results Available,Solid Tumor|Triple Negative Breast Cancer|Microsatellite Stable Colorectal Cancer,Biological: TBio-6517|Biological: Pembrolizumab,"March 9, 2020","Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|Sylvester Comprehensive Cancer Center / UMHC, Miami, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mayo Clinic, Rochester, Minnesota, United States|The Billings Clinic, Billings, Montana, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04301011
Principal Investigator,Trevor Royce,UNC Chapel Hill,,NCT04292860,trevor royce,trevor,male,0.99,6317,339,NCT04292860,Reverse Axillary Mapping in Breast Radiation Treatment Planning,Not yet recruiting,No Results Available,Breast Cancer|Lymphedema,,"March 3, 2020",,https://ClinicalTrials.gov/show/NCT04292860
Principal Investigator,"Winnie SS Chee, PhD",International Medical University,,NCT04400552,winnie ss chee,winnie,female,0.88,4657,340,NCT04400552,Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients,Recruiting,No Results Available,Cancer of Breast|Cancer Colon,Dietary Supplement: ONS Pre-op + ONS Post-op|Dietary Supplement: ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Dietary Supplement: Usual intake Pre-op + ONS Post-op,"May 22, 2020","International Medical University, Kuala Lumpur, Malaysia",https://ClinicalTrials.gov/show/NCT04400552
Principal Investigator,"Terje Alraek, PhD","School of Health Sciences, Kristiania University College",,NCT04418115,terje alraek,terje,male,0.91,963,341,NCT04418115,Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option?,Not yet recruiting,No Results Available,"Fatigue|Depression, Anxiety|Insomnia|Hot Flashes|Quality of Life",Other: Acupuncture; based on Tradidtional Chinese Medicine,"June 5, 2020",,https://ClinicalTrials.gov/show/NCT04418115
Study Chair,"Gunilla Björling, PhD",The Swedish Red Cross University College,,NCT04324346,gunilla björling,gunilla,female,0.99,1377,344,NCT04324346,Central Catheters Used for Chemotherapy in Women With Breast Cancer,Recruiting,No Results Available,Catheter Related Complications,Drug: FEC75 (or EC90) x 6|Drug: FEC100 + Taxotere (EC90 + Taxotere) 3+3|Drug: Paclitaxel,"March 27, 2020","Onkologiska kliniken, Karolinska University Hospital, Danderyd Hospital, Stockholm, Sweden",https://ClinicalTrials.gov/show/NCT04324346
Principal Investigator,"Celina Shirazipour, PhD",Cedars-Sinai Medical Center,,NCT04282967,celina shirazipour,celina,female,0.98,5320,348,NCT04282967,Streaming Web-based Exercise At Home: A Pilot Study,Not yet recruiting,No Results Available,Prostate Cancer|Breast Cancer Female,Behavioral: Exercise,"February 25, 2020","Cedars Sinai Medical Center, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04282967
Principal Investigator,Nestor Esnaola,Fox Chase Cancer Center,,NCT04290585,nestor esnaola,nestor,male,0.98,6358,350,NCT04290585,Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography,Completed,No Results Available,Female Breast Carcinoma|Healthy Subject,Other: Questionnaire Administration|Behavioral: Telephone-Based Intervention,"March 2, 2020","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04290585
Principal Investigator,"Sian Taylor-Phillips, PhD",University of Warwick,,NCT04365114,sian taylor-phillips,sian,female,0.88,1397,353,NCT04365114,Patient Outcomes From Second Film-readers and Test Threshold Relaxation in Breast Screening,Enrolling by invitation,No Results Available,Breast Cancer|Ductal Carcinoma in Situ,Diagnostic Test: Breast Screening Mammography with single reader|Diagnostic Test: Breast screening mammography with two readers|Diagnostic Test: Test threshold,"April 28, 2020","Univesity of Warwick, Coventry, Warwickshire, United Kingdom",https://ClinicalTrials.gov/show/NCT04365114
Principal Investigator,"Stefanie Woodard, MD",University of Alabama at Birmingham,,NCT04340180,stefanie woodard,stefanie,female,0.97,25370,354,NCT04340180,Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction,Not yet recruiting,No Results Available,Breast Benign Tumor|Breast Malignant Tumor,Drug: Standard of Care (SOC) gadolinium Breast MRI|Drug: reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.,"April 9, 2020","The Kirklin Clinic, Birmingham, Alabama, United States",https://ClinicalTrials.gov/show/NCT04340180
Principal Investigator,"Matthew Covington, MD",Huntsman Cancer Institute/ University of Utah,,NCT04252859,matthew covington,matthew,male,1.0,35521,355,NCT04252859,[18F]Fluoroestradiol Imaging of Invasive Lobular Carcinoma Using PET/CT,Not yet recruiting,No Results Available,Invasive Lobular Breast Carcinoma,Drug: [18F]Fluoroestradiol (FES) PET/CT,"February 5, 2020",,https://ClinicalTrials.gov/show/NCT04252859
Study Director,"Matthew Griffiths, MBBS, MD",Mid Essex NHS trust,,NCT04350411,matthew griffiths,matthew,male,1.0,35521,368,NCT04350411,Comparison of PEAK PlasmaBlade™ to Conventional Diathermy in Abdominal Based Free Flap Breast Reconstruction,Completed,No Results Available,Breast Reconstruction|Breast Cancer,Device: Conventional diathermy|Device: PEAK PlasmaBlade™,"April 17, 2020","Mid Essex NHS trust, Chelmsford, Essex, United Kingdom",https://ClinicalTrials.gov/show/NCT04350411
Principal Investigator,"Thessa R Friebel, MSc",Mid Essex NHS trust,,NCT04350411,thessa r friebel,thessa,female,0.98,233,368,NCT04350411,Comparison of PEAK PlasmaBlade™ to Conventional Diathermy in Abdominal Based Free Flap Breast Reconstruction,Completed,No Results Available,Breast Reconstruction|Breast Cancer,Device: Conventional diathermy|Device: PEAK PlasmaBlade™,"April 17, 2020","Mid Essex NHS trust, Chelmsford, Essex, United Kingdom",https://ClinicalTrials.gov/show/NCT04350411
Study Director,"Selim Cellek, MD, PhD",Anglia Ruskin University,,NCT04350411,selim cellek,selim,male,0.97,22868,368,NCT04350411,Comparison of PEAK PlasmaBlade™ to Conventional Diathermy in Abdominal Based Free Flap Breast Reconstruction,Completed,No Results Available,Breast Reconstruction|Breast Cancer,Device: Conventional diathermy|Device: PEAK PlasmaBlade™,"April 17, 2020","Mid Essex NHS trust, Chelmsford, Essex, United Kingdom",https://ClinicalTrials.gov/show/NCT04350411
Study Director,"Jens N Børglum, PhD, MD","Department of Anaesthesiology, Zealand University Hospital, Roskilde",,NCT04248179,jens n børglum,jens,male,0.99,23807,356,NCT04248179,The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery.,Recruiting,No Results Available,Breast Cancer|Ductal Carcinoma in Situ,Drug: Ropivacaine injection|Drug: Saline 0.9%|Drug: Sufentanil and PONV prophylaxis,"January 30, 2020","Department of Anaesthesiology and Intensive Care Medicine, Zealand University Hospital, Roskilde, Roskilde, Zealand Region, Denmark",https://ClinicalTrials.gov/show/NCT04248179
Principal Investigator,Maria E Fernandez,"The University of Texas Health Science Center, Houston",,NCT04397744,maria e fernandez,maria,female,0.98,334287,357,NCT04397744,Unidas Por Vida y Salud: Increasing Breast and Cervical Cancer Screening in El Paso,Completed,No Results Available,Breast Cancer|Cervical Cancer,Behavioral: Unidas por Vida y Salud prevention program,"May 21, 2020","The University of Texas Health Science Center at Houston, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04397744
Principal Investigator,"Maria C. Katapodi, PhD","Department of Clinical Research, University of Basel",,NCT04214210,maria c. katapodi,maria,female,0.98,334287,381,NCT04214210,The DIALOGUE Study: Swiss-Korean Billateral Collaboration,Not yet recruiting,No Results Available,Hereditary Cancer|Breast Cancer|Ovarian Cancer,Other: Adapted Family Gene Toolkit|Other: Targeted intervention,"January 2, 2020","University Hospital Basel, Basel, Switzerland|Istituto Oncologico della Zvizzera Italiana, Bellinzona, Switzerland|Universitatklinik fur Medizinische Onkologie, Inselspital, Bern, Switzerland|Unite d'Oncogenetique et de Prevention des Cancers, Geneva, Switzerland",https://ClinicalTrials.gov/show/NCT04214210
Principal Investigator,Lara Savas,"The University of Texas Health Science Center, Houston",,NCT04426019,lara savas,lara,female,0.98,39309,358,NCT04426019,Using a Lay Health Worker Program to Increase Breast and Cervical Cancer Screening in Low-Income Hispanic Women,Completed,No Results Available,Breast Cancer|Cervical Cancer,Behavioral: CLS Intervention|Behavioral: No CLs intervention,"June 11, 2020","The University of Texas Health Science Center at Houston, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04426019
Principal Investigator,"Dirk Rades, MD","Department of Radiation Oncology, University of Lübeck, Germany",,NCT04335409,dirk rades,dirk,male,0.99,23736,359,NCT04335409,Pneumonitis After Radiotherapy of Breast or Lung Cancer,Not yet recruiting,No Results Available,Breast Cancer|Lung Cancer,Diagnostic Test: Questionnaire|Other: Mobile Application,"April 6, 2020",,https://ClinicalTrials.gov/show/NCT04335409
Study Director,"Birna Baldursdottir, PhD",Reykjavik University,,NCT04418856,birna baldursdottir,birna,female,0.89,54,362,NCT04418856,The Effects of Light Therapy to Treat Cancer-related Side Effects,Not yet recruiting,No Results Available,Breast Cancer|Circadian Rhythms|Fatigue|Sleep Disturbance|Cognitive Impairment|Inflammatory Response|Depression,Device: Light Glasses (Experimental)|Device: Light Glasses (Comparison),"June 5, 2020",,https://ClinicalTrials.gov/show/NCT04418856
Study Director,"Hege Kersten, PhD",Sykehuset Telemark,,NCT04273464,hege kersten,hege,female,0.9,365,363,NCT04273464,Breast Reconstruction With Autologous Tissue: Microsurgery or Fat Grafting?,"Active, not recruiting",No Results Available,Breast Cancer|Mammaplasty,Procedure: Brava-group|Procedure: DIEP-group,"February 18, 2020","Telemark Hospital, Skien, Telemark, Norway",https://ClinicalTrials.gov/show/NCT04273464
Study Chair,Marian Gutowski,Institut du Cancer de Montpellier,,NCT04342546,marian gutowski,marian,male,0.62,32263,366,NCT04342546,Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction,Not yet recruiting,No Results Available,Breast Cancer|Capsular Contracture Associated With Breast Implant,Device: NovaGray RILA Breast® test,"April 13, 2020","Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmette, Marseille, France|Institut du Cancer de Montpellier, Montpellier, France|Hôpital Tenon, Paris, France|Institut de Cancérologie de l'Ouest, Saint-Herblain, France",https://ClinicalTrials.gov/show/NCT04342546
Principal Investigator,Wonshik Han,Seoul National University Hospital,,NCT04303715,wonshik han,wonshik,male,1.0,6,367,NCT04303715,No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography,Not yet recruiting,No Results Available,Breast Cancer|Sentinel Lymph Node,Procedure: No SLNB|Procedure: SLNB,"March 11, 2020","Seoul National University Hospital, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04303715
Principal Investigator,"Don S Dizon, MD",Rhode Island Hospital,,NCT04221607,don s dizon,don,male,0.98,21894,370,NCT04221607,An Intimacy Intervention for Couples Completing Breast or Prostate Cancer,Recruiting,No Results Available,Sexual Dysfunction|Breast Cancer|Prostate Cancer,Other: Sensate Focus exercise,"January 9, 2020","Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States",https://ClinicalTrials.gov/show/NCT04221607
Principal Investigator,"Shane Gallagher, MSc",Study Principal Investigator,,NCT04435639,shane gallagher,shane,male,0.89,11605,371,NCT04435639,Using an Adjustable Compression Garment for Secondary Upper Limb Lymphoedema,Not yet recruiting,No Results Available,Lymphedema of Upper Arm,Device: Manual lymph drainage & adjustable compression sleeve.|Device: Control Manual Lymphatic drainage & Coban compression bandage..,"June 17, 2020",,https://ClinicalTrials.gov/show/NCT04435639
Principal Investigator,"Montse Garcia, PhD",Catalan Institute of Oncology,,NCT04343950,montse garcia,montse,female,0.99,15185,372,NCT04343950,SMS Messaging as a Tool to Improve Cancer Screening Programs,Not yet recruiting,No Results Available,Mass Screening|Colorectal Cancer|Breast Cancer,Behavioral: SMS reminders to enhance colorectal cancer screening|Behavioral: SMS reminders to return the fecal immunochemical test at the pharmacy in CRC screening:|Behavioral: Invitation by SMS to previous participants in breast cancer screening:,"April 14, 2020",,https://ClinicalTrials.gov/show/NCT04343950
Principal Investigator,"Andrzej Piatkowski de Grzymala, MD, MSc",Maastricht University Medical Center,,NCT04261829,andrzej piatkowski de grzymala,andrzej,male,0.99,40041,375,NCT04261829,AFT: Introduction of a Full Breast Reconstructive Method,Not yet recruiting,No Results Available,Breast Cancer|Reconstructive Surgery|Breast Reconstruction,Procedure: Autologous Fat Transfer,"February 10, 2020",,https://ClinicalTrials.gov/show/NCT04261829
Principal Investigator,Pooja P Advani,Mayo Clinic,,NCT04256512,pooja p advani,pooja,female,0.98,1476,378,NCT04256512,Cryotherapy to Prevent Taxane-induced Sensory Neuropathy of the Hands and Feet,Recruiting,No Results Available,Breast Cancer|Peripheral Neuropathy|Chemotherapy-induced Peripheral Neuropathy,Device: Elasto Gel® Therapy Mittens and Foot Wraps,"February 5, 2020","Mayo Clinic in Florida, Jacksonville, Florida, United States",https://ClinicalTrials.gov/show/NCT04256512
Principal Investigator,"Catharine Wang, PhD",BU School of Public Health,,NCT04407611,catharine wang,catharine,female,0.96,122,379,NCT04407611,Scalable Communication Modalities for Returning Genetic Research Results,Not yet recruiting,No Results Available,Hereditary Breast and Ovarian Cancer,Behavioral: Online modality|Behavioral: Genetic counselor follow-up,"May 29, 2020",,https://ClinicalTrials.gov/show/NCT04407611
Principal Investigator,"Farshad SeyedNejad, MD",Tabriz University of Medical Sciences,,NCT04239560,farshad seyednejad,farshad,male,0.98,1056,385,NCT04239560,Preventive Effect of Boron-based Gel on Radiation Dermatitis,Completed,No Results Available,Radiodermatitis,Drug: Boron-based Gel (Fibore)|Drug: Placebos,"January 27, 2020","Shahid Madani Medical & Training Hospital - Department of Radiotherapy, Tabriz, East Azarbaijan, Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04239560
Principal Investigator,"Huma Rana, MD",Dana-Farber Cancer Institute,,NCT04330716,huma rana,huma,female,0.85,496,387,NCT04330716,"Genetic Testing for Breast, Ovarian, Pancreatic and Prostate Cancers",Not yet recruiting,No Results Available,Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Metastatic Prostate Cancer,Behavioral: In Person Counseling|Behavioral: Educational Video,"April 1, 2020","Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, Weymouth, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04330716
Principal Investigator,"Gayathri Nagaraj, MD",Loma Linda University Cancer Center,,NCT04266353,gayathri nagaraj,gayathri,female,0.98,264,389,NCT04266353,Effect of Resveratrol on Serum IGF2 Among African American Women,"Active, not recruiting",No Results Available,Chemoprevention,Dietary Supplement: Resveratrol (RSV),"February 12, 2020","Loma Linda University Cancer Center, Loma Linda, California, United States",https://ClinicalTrials.gov/show/NCT04266353
Principal Investigator,"María Torres-Lacomba, PhD",University of Alcalá,,NCT04338334,maría torres-lacomba,maría,female,0.99,232436,391,NCT04338334,Effectiveness of Cohesive Bandage on Axillary Web Syndrome After,Recruiting,No Results Available,Axillary Web Syndrome,Other: Manual drainage & arm therapeutic exercise|Other: Cohesive bandaging & arm therapeutic exercise,"April 8, 2020","María Torres-Lacomba, Alcalá De Henares, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04338334
Principal Investigator,Allison Magnuson,University of Rochester,,NCT04230941,allison magnuson,allison,female,0.93,4385,392,NCT04230941,Memory and Attention Adaptation Training-Geriatrics (MAAT-G),Not yet recruiting,No Results Available,Cancer-related Problem/Condition|Cognitive Impairment,Behavioral: MAAT-G,"January 18, 2020",,https://ClinicalTrials.gov/show/NCT04230941
Study Chair,"Erik H Jakobsen, MD",Vejle Hospital,,NCT04440930,erik h jakobsen,erik,male,0.99,36091,394,NCT04440930,White Tea for Prevention of Chemotherapy Induced Mucositis,Not yet recruiting,No Results Available,Oral Mucositis,Other: White tea|Other: Salt water with soda,"June 22, 2020","Department of Oncology, Vejle Hospital, Vejle, Denmark",https://ClinicalTrials.gov/show/NCT04440930
Study Director,"Reshma Rangwala, MD",Genmab,,NCT04424641,reshma rangwala,reshma,female,0.97,464,395,NCT04424641,A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Subjects With Malignant Solid Tumors,Not yet recruiting,No Results Available,Dose Escalation Part: Locally Advanced or Metastatic Solid Tumor(s)|Expansion Part: Prostate Cancer|Expansion Part: Esophageal Cancer|Expansion Part: Triple Negative Breast Cancer (TNBC)|Expansion Part: Squamous Cell Carcinoma of Head and Neck (SCCHN)|Expansion Part: Non-small Cell Lung Cancer (NSCLC)|Expansion Part: Bladder Cancer|Expansion Part: Uterine Cancer,Biological: GEN1044 is an IgG1 bispecific antibody targeting CD3 and 5T4.,"June 11, 2020","Tennesse Oncology, PLLC - Nashville, Nashville, Tennessee, United States|Rigshospitalet (Copenhagen University Hospital), Copenhagen, Denmark|Chaim Sheba Medical Center, Ramat Gan, Israel|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Fundacion Jimenez Diaz, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04424641
Principal Investigator,"Xiaonan Cui, MD,PhD",The First Affiliated Hospital of Dalian Medical University,,NCT04215861,xiaonan cui,xiaonan,male,0.61,28,400,NCT04215861,"Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy",Recruiting,No Results Available,Lung Cancer|Liver Cancer|Stomach Cancer|Breast Cancer,,"January 2, 2020","The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China",https://ClinicalTrials.gov/show/NCT04215861
Study Director,"Christina May Moran de Brito, MD, PhD",Instituto do Câncer do Estado de São Paulo,,NCT04267315,christina may moran de brito,christina,female,0.98,35006,401,NCT04267315,Trigger Point Injections for Post-Mastectomy Pain Syndrome,Not yet recruiting,No Results Available,"Post-mastectomy Pain Syndrome|Myofascial Pain Syndrome|Trigger Point Pain, Myofascial|Breast Cancer",Procedure: Trigger point injection|Procedure: Subcutaneous saline injection|Other: Comprehensive Rehabilitation program,"February 12, 2020",,https://ClinicalTrials.gov/show/NCT04267315
Principal Investigator,Jose A Rauh-Hain,M.D. Anderson Cancer Center,,NCT04257045,jose a rauh-hain,jose,male,0.98,451671,405,NCT04257045,Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives,Recruiting,No Results Available,Breast Carcinoma|Deleterious CDH1 Gene Mutation|Deleterious DICER1 Gene Mutation|Deleterious SMARCA4 Gene Mutation|Deleterious STK11 Gene Mutation|Endometrial Carcinoma|Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Carcinoma,Other: Interview|Other: Questionnaire Administration|Other: Survey Administration,"February 5, 2020","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|M D Anderson Cancer Center, Houston, Texas, United States",https://ClinicalTrials.gov/show/NCT04257045
Study Director,Medical Monitor,Asana BioSciences,,NCT04410224,medical monitor,medical,male,0.66,35,406,NCT04410224,Study of ASN004 in Patients With Advanced Solid Tumors,Not yet recruiting,No Results Available,"Breast Cancer|Breast Neoplasms|Breast Adenocarcinoma|Breast Cancer Recurrent|Breast Cancer Metastatic|Breast Cancer Invasive|Non-small Cell Lung Cancer|Non-small Cell Carcinoma|Non-small Cell Lung Cancer Recurrent|Non-Small Cell Squamous Lung Carcinoma|Non-Small Cell Adenocarcinoma|Non-small Cell Lung Cancer Metastatic|Colorectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma|Colorectal Adenocarcinoma|Colorectal Cancer Metastatic|Colorectal (Colon or Rectal) Cancer|Colon Cancer|Colon Neoplasm|Ovarian Cancer|Ovarian Neoplasm|Ovarian Cancer Recurrent|Carcinoma, Ovarian Epithelial|Carcinoma Ovary|Carcinoma Colon|Carcinoma Breast|Carcinoma, Non-Small-Cell Lung",Drug: ASN004,"June 1, 2020",,https://ClinicalTrials.gov/show/NCT04410224
Principal Investigator,"Yulei Jiang, Ph.D",University of Chicago,,NCT04260620,yulei jiang,yulei,female,0.7,20,408,NCT04260620,Delphinus SoftVue™ ROC Reader Study (DMT SV RRS3),Enrolling by invitation,No Results Available,Breast Cancer Detection|Dense Breast Parenchyma|Benign Breast Findings|Normal Breast Screening|Abnormal Breast Screening,Device: Reading of Automated Breast Ultrasound in conjunction with Screening Mammography,"February 7, 2020","Delphinus Medical Technologies, Inc., Novi, Michigan, United States",https://ClinicalTrials.gov/show/NCT04260620
Study Director,"Ocellaris Pharma, Inc","Ocellaris Pharma, Inc.",,NCT04260802,ocellaris pharma,ocellaris,male,1.0,2,410,NCT04260802,A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers,Not yet recruiting,No Results Available,Cancer|Neoplasms|Metastatic Cancer|Triple Negative Breast Cancer|Gastric Cancer|Cervical Cancer|Ovarian Cancer|Hepatocellular Carcinoma|Squamous Cell Carcinoma of Head and Neck|Urothelial Carcinoma|Urothelial Neoplasm|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Locally Advanced Solid Tumor|Locally Advanced Malignant Neoplasm|Squamous Cell Carcinoma|Sarcoma|Merkel Cell Carcinoma|Bladder Cancer,Drug: OC-001|Drug: OC-001 in Combination,"February 7, 2020","Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Jewish General Hospital - Clinical Research Unit, Montreal, Quebec, Canada|Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04260802
Principal Investigator,"Shiraz I Mishra, MBBS, PhD",University of New Mexico School of Medicine,,NCT04259762,shiraz i mishra,shiraz,male,0.71,567,411,NCT04259762,Enhancing Cancer Prevention and Control Pathways—Native Health Initiative,Not yet recruiting,No Results Available,"Cancer, Breast|Cancer, Colon|Cancer, Cervix","Behavioral: Breast, Colorectal, and Cervical Cancer Screening Interventions","February 6, 2020",,https://ClinicalTrials.gov/show/NCT04259762
Principal Investigator,"Marisa Weiss, MD",Main Line Health System,,NCT04398446,marisa weiss,marisa,female,0.98,25702,414,NCT04398446,Effect of Hemp-CBD on Patients With CIPN,Recruiting,No Results Available,Chemotherapy-induced Peripheral Neuropathy|Colorectal Cancer Stage II|Colorectal Cancer Stage III|Breast Cancer|Ovarian Cancer,Drug: Hemp-based CBD|Other: Placebo oral tablet,"May 21, 2020","Lankenau Medical Center, Wynnewood, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04398446
Principal Investigator,Bijan Najafi,Baylor College of Medicine,,NCT04307355,bijan najafi,bijan,male,0.98,500,415,NCT04307355,Continuous Diffusion of Oxygen Treatment for Incision Wounds for Cancer Patients,Not yet recruiting,No Results Available,Surgical Wound|Breast Cancer|Mastectomy|Tissue Necrosis|Incision Wound,Device: Transcu O2®,"March 13, 2020",,https://ClinicalTrials.gov/show/NCT04307355
Principal Investigator,"Udo Rudloff, M.D.",National Cancer Institute (NCI),,NCT04222413,udo rudloff,udo,male,0.99,4182,418,NCT04222413,Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors,Not yet recruiting,No Results Available,Advanced Solid Tumors|Metastatic Pancreatic Cancer|Pediatric Solid Tumor|Advanced Breast Cancer|Malignant Peripheral Nerve Sheath Tumor,Drug: Metarrestin,"January 10, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",https://ClinicalTrials.gov/show/NCT04222413
Principal Investigator,"Jason L. Vassy, MD, MPH, SM",Harvard Medical School,,NCT04331535,jason l. vassy,jason,male,0.99,63418,419,NCT04331535,The Genomic Medicine at VA Study,Recruiting,No Results Available,Coronary Artery Disease|Atrial Fibrillation|Type 2 Diabetes|Colorectal Cancer|Breast Cancer|Prostate Cancer,Diagnostic Test: Polygenic risk score (PRS),"April 2, 2020","VA Boston Healthcare System, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04331535
Principal Investigator,"Jia Guo, RN, PhD",Central South Univeristy,,NCT04326660,jia guo,jia,female,0.63,2077,420,NCT04326660,SCOPE-Chinese Women Study,Not yet recruiting,No Results Available,"Cancer, Breast|Obesity, Abdominal",Other: SCOPE-Chinese Women,"March 30, 2020","University of California, San Francisco, San Francisco, California, United States|Central South University, Yuelu, Changsha, Hunan, China",https://ClinicalTrials.gov/show/NCT04326660
Principal Investigator,"Janessa Laskin, MD",BC Cancer,,NCT04273061,janessa laskin,janessa,female,0.99,154,429,NCT04273061,Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity,Recruiting,No Results Available,Breast Cancer|Lung Cancer|Gastrointestinal Cancer|Genitourinary Cancer|Gynecologic Cancer|Sarcoma|Unknown Primary Tumors|Head and Neck Cancer|Skin Cancer,Drug: Atezolizumab,"February 17, 2020","BC Cancer, Vancouver, British Columbia, Canada",https://ClinicalTrials.gov/show/NCT04273061
Principal Investigator,"Matthieu Picard, M.D.",Ciusss de L'Est de l'Île de Montréal,,NCT04237090,matthieu picard,matthieu,male,0.99,18665,430,NCT04237090,Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel,Recruiting,No Results Available,Breast Cancer|Lung Cancer|Ovarian Cancer|Oesophageal Cancer|Head Cancer Neck|Cervical Cancer|Endometrial Cancer,Drug: Diphenhydramine|Drug: Cetirizine|Drug: Lactose pill|Drug: Sodium chloride 0.9%,"January 22, 2020","CIUSSS de l'Est-de-l'île-de-Montréal, Montréal, Quebec, Canada",https://ClinicalTrials.gov/show/NCT04237090
Study Director,"Natalya Nazarenko, MD","Seattle Genetics, Inc.",,NCT04389632,natalya nazarenko,natalya,female,0.99,5607,433,NCT04389632,A Study of SGN-B6A in Advanced Solid Tumors,Recruiting,No Results Available,Non-small Cell Lung Cancer|Head and Neck Squamous Cell Cancer|Breast Cancer|Esophageal Cancer|Ovarian Cancer|Cutaneous Squamous Cell Cancer|Exocrine Pancreatic Adenocarcinoma|Bladder Cancer|Cervical Cancer|Gastric Cancer,Drug: SGN-B6A,"May 15, 2020","Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04389632
Principal Investigator,Virginie Bichon,"AP-HP, Hôpital Européen Georges Pompidou, Paris",,NCT04235556,virginie bichon,virginie,female,0.98,52720,434,NCT04235556,Integrated Care Pathway in Oncology (PASSION),Recruiting,No Results Available,Colon Cancer|Gastric Cancer|Pancreatic Cancer|Thoracic Neoplasms|Breast Cancer|Ovarian Cancer|Bladder Cancer|Prostate Cancer,Behavioral: Care pathway unit,"January 22, 2020","AP-HP Hôpital européen Georges-Pompidou, Paris, France",https://ClinicalTrials.gov/show/NCT04235556
Principal Investigator,"Aadel Chaudhuri, M.D., Ph.D.",Washington University School of Medicine,,NCT04354064,aadel chaudhuri,aadel,male,0.96,124,436,NCT04354064,Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors,Recruiting,No Results Available,Healthy Volunteer|Prostate Cancer|Head and Neck Cancer|Esophageal Cancer|Genitourinary Cancer|Sarcoma|Breast Cancer|Colon Cancer|Gastrointestinal Cancer|Solid Tumor Cancer|Lung Cancer|Skin Cancer|Melanoma,,"April 21, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",https://ClinicalTrials.gov/show/NCT04354064
